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Incidence and survival of primary dermatofibrosarcoma protuberans in the United States
KL Kreicher, DE Kurlander, JS Barnholtz-Sloan, HR Gittleman and JS Bordeaux Case Western 
Reserve University, Cleveland, OH
We sought to describe the incidence of and survival from primary dermatofibrosarcoma protuberans 
(DFSP) in the United States. We used data from the 18 registries of the Surveillance, Epidemiology, 
and End Results Program from 2000-2010 to calculate the incidence of and survival from primary 
DFSP. Overall incidence was 0.41 per 100,000 person years. Incidence remained steady over the 
study period. The trunk was the most common anatomic site for all age groups except for men 
over the age of 80. Incidence among women was 1.14 times higher than men (95% CI of rate ratio: 
1.07-1.22). Incidence among blacks was almost 2 times the rate among whites (95% CI of rate 
ratio: 1.8-2.1). 10-year relative survival of DFSP was 99.1% (95% CI: 97.6% - 99.7%). Increasing 
age, male sex, and black race were associated with higher all-cause mortality. Anatomic location 
of the upper limb, lower limb, and head were associated with higher mortality as compared to the 
most common location of the trunk. The epidemiology of DFSP differs from most skin cancers. 
Our data show that incidence of DFSP has not changed over the last decade. Incidence among 
blacks is almost twice that of whites. This is the first report showing statistically higher incidence 
among women than men. Worse survival is associated with increased age, male sex, black race 
and anatomic location of the limbs and head.    
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Intake of antihypertensives suspected, according to published reports, of triggering pemphigus 
by pemphigus patients: The large-scale problem
M Dmochowski, P Pietkiewicz, J Gornowicz-Porowska and M Bowszyc-Dmochowska 
Autoimmune Blistering Dermatoses Section, Dermatology, Poznan University of Medical 
Sciences, Poznan, Poland
While there are numerous case reports on antihypertensives (AH)-induced pemphigus, detailed 
studies showing the scale of the issue are needed. Here, the hospital records regarding AH intake 
of 117 patients with active IgG-mediated pemphigus (including 7 with malignancy-associated 
non-paraneoplastic pemphigus and 4 with cutaneous scarring-associated pemphigus), diagnosed 
with a combination of microscopic (H+E and direct immunofluorescence of perilesional tissue and 
plucked scalp hair with IgG4 deposits evaluation) and biochemical-molecular (ELISA for IgG/IgG4 
antibodies to desmogleins 3/1) techniques, in the last thirteen years were analyzed in a setting of 
a Central Europe university dermatology department. Eight of 48 mucocutaneous (mc) pemphigus 
vulgaris (PV), 8 of 27 mucosal-dominant PV, none of 2 cutaneous PV, 13 of 38 pemphigus folia-
ceus (PF), and 1 of 2 mc PV shifting to PF cases were taking at least one AH suspected, according 
to published data, of inducing pemphigus. Ramipril and enalapril were the most frequently taken 
AH (each by 11 pemphigus patients), followed by captopril and indapamide (10 and 7 pemphigus 
patients, respectively). We suggest here, after evaluating clinical and laboratory data, both ours and 
literature, that the still poorly understood issue of so-called drug-induced pemphigus (DIP), which 
seems to be a large-scale problem necessitating ex vivo testing, should be subdivided at least into 
five categories: triggering of pemphigus autoimmunity by DIP-associated drugs without clinically 
overt pemphigus, DIP triggered exclusively by DIP-associated drugs, DIP triggered multifactorially 
including DIP-associated drugs, pemphigus triggered by not DIP-associated drugs with the course 
modified by DIP-associated drugs, idiopathic pemphigus with the course modified by DIP-associated 
drugs. Such a categorization might benefit patients, as they have variable severity and prognosis of 
their pemphigus, by individualizing their management.    
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Appearance-based video education is more effective than health-based video education in 
promoting sunscreen use among adolescents: A randomized controlled trial
W Tuong1 and AW Armstrong2 1 UC Davis School of Medicine, Sacramento, CA and 2 
University of Colorado Denver School of Medicine, Aurora, CO
Skin cancer prevention interventions include appearance-based or health-based messages to educate 
schoolchildren. The study objective was to compare the effectiveness of appearance-based video 
education with that of health-based video education in improving sunscreen use and knowledge. 
In a randomized controlled trial, participants viewed an appearance-based video on ultraviolet 
(UV)-induced premature aging or a health-based video emphasizing UV exposure and skin can-
cer risk. Sunscreen use was assessed at baseline and at 6-weeks post-intervention. A satisfaction 
survey asked subjects to rate the usefulness, appeal, and presentation quality of the videos. Fifty 
high school students participated in the study in 2012. Within-group analysis showed that the 
health-based video resulted in a non-significant increase in sunscreen use (0.9 ± 1.9 days per week, 
p=0.096). The appearance-based video resulted in a significant increase in sunscreen use (2.8 ± 2.2, 
p<0.001). Between-group comparisons revealed that those randomized to the appearance-based 
video applied sunscreen more often than those randomized to the health-based video (2.2 ± 1.4 
versus 0.2 ± 0.6, p<0.001). Although knowledge significantly improved in both study groups after 
video education, the difference in improvement after 6-weeks was not significant between those 
randomized to the appearance-based video (1.2 ± 2.0) and health-based video (0.9 ± 1.7), p=0.651. 
The appearance-based video received a higher usefulness rating than the health-based video (8.1 ± 
0.2 versus 6.4 ± 0.3, respectively; p<0.001). The appeal of the appearance-based video (8.3 ± 0.2) 
was also higher than the health-based video (6.6 ± 0.3, p<0.001). The quality rating between the 
appearance-based video (7.8 ± 0.3) and health-based video (8.1 ± 0.3) was not significantly different, 
p=0.517. Appearance-based education can improve sunscreen knowledge, promote sunscreen use, 
and be easily disseminated by video.    
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Palmoplantar psoriasis is associated with greater impairment of health-related quality of life 
compared to moderate to severe plaque psoriasis: Results from the Dermatology Clinical 
Effectiveness Research Network (DCERN)
J Chung,1 KC Duffin,2 J Takeshita,1 D Shin,1 GG Krueger,2 AD Robertson,3 A Troxel,1 
AS Van Voorhees,1 E Edson-Heredia4 and J Gelfand1 1 University of Pennsylvania Perelman 
School of Medicine, Philadelphia, PA, 2 University of Utah School of Medicine, Salt Lake 
City, UT, 3 The National Psoriasis Foundation, Portland, OR and 4 Eli Lilly and Company, 
Indianapolis, IN
Although palmoplantar psoriasis is often recognized as a potentially disabling variant of psoriasis, 
there are few data regarding its impact on health-related quality of life (HRQoL). In a cross-sec-
tional study, we compared clinical characteristics and patient-reported outcomes in patients with 
palmoplantar psoriasis (N=66) and moderate to severe plaque psoriasis (N=1153) presenting at 10 
dermatology sites across the US. All included patients were currently receiving systemic or light 
treatment for psoriasis. The outcomes were as follows: Dermatology Life Quality Index (DLQI) 
score > 5 (moderate-extremely large HRQoL impairment); EuroQol Health Questionnaire (EQ-5D) 
index score greater than the sample median; having problems associated with the five dimensions 
of EQ-5D (mobility, self-care, usual activities, pain, anxiety); and heavy topical prescription use (at 
least twice daily during the previous week). In adjusted analyses, patients with palmoplantar psoriasis 
were more likely to report DLQI scores that correspond to at least a moderate impact on quality of 
life (odds ratio [OR] 2.08; 95% confidence interval [CI], 1.20-3.61); problems with mobility (OR 
1.98; 95% CI, 1.10-3.58), self-care (OR 3.12; 95% CI, 1.24-7.86), and usual activities (OR 2.47; 
95% CI, 1.44-4.22); and heavy topical prescription use (OR 2.81; 95% CI, 1.63-4.85) than those 
with plaque psoriasis. Our findings suggest that patients with palmoplantar psoriasis suffer from 
greater HRQoL impairment and are more likely to report heavy use of topical prescriptions than 
those with moderate to severe plaque psoriasis.    
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Eczema remains active with age
K Abuabara,1,2 O Hoffstad,2 AB Troxel2 and DJ Margolis1,2 1 Dermatology, University 
of Pennsylvania, Philadelphia, PA and 2 Biostatistics and Epidemiology, University of 
Pennsylvania, Philadelphia, PA
This prospective observational cohort study aimed to examine the longitudinal course of disease 
activity in children with eczema. Self-reported disease control was assessed every six months for a 
median of 13 assessments (interquartile range 7-15) among 7,350 patients in the Pediatric Eczema 
Elective Registry with mild to moderate eczema. Seventy-three percent of participants reported 
onset of disease by two years of age. The mean age at enrollment was 7.4 years (standard deviation 
4.2 years). The average level of control across the population by the age of visit remained fairly 
constant over time. There was a significant trend towards a slightly higher proportion of visits with 
complete control and a slightly lower proportion of visits with poor control, but no significant 
differences in good and limited control with increasing age. Overall, patients reported complete 
control at 13% of assessments; only 31% of the population ever reported a 6-month period with 
complete disease control during the observation period. Examining the combination of treatment 
with self-reported disease control showed that 25% of patients with >2 visits achieved at least one 
period of ‘remission’ (i.e., complete disease control and no use of prescription medications for 
eczema). Among these patients, 47% subsequently reported disease activity or medication use, 
suggesting that a minority of children outgrew their disease during the period of observation. The 
average number of visits to a health care provider for eczema decreased over time, even among 
patients who never achieved complete control of their disease, suggesting that patients may learn 
to manage their disease on their own.    
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Validation and comparison of quality of life (QoL) measures for topical 5-fluorouracil 
treatment
H Pomerantz,1,2 M Chren,3 R Lew4 and MA Weinstock1,2 1 VA Medical Center, Providence, 
RI, 2 Brown University, Providence, RI, 3 University of California, San Francisco, CA and 4 
VA Cooperative Studies Coordinating Center, Boston, MA
Skindex, a generic dermatology QoL instrument, and Skin Cancer Index (SCI), a skin cancer-specific 
QoL instrument, have not been compared in the skin cancer population and studied in topical 5-FU 
treatment. The VAKCC trial randomized 941 veterans with at least 2 prior keratinocyte carcinomas 
to either receive topical 5% 5-FU cream (n=472) or vehicle cream (n=469) on the face and ears 
twice daily for up to 4 weeks. Subscales of Skindex (emotion, symptom, function) and SCI (emo-
tion, social, appearance) were compared at baseline, at 4 weeks, and at 1 year. All subscales of 
Skindex and SCI were significantly correlated with each other at baseline and at 4 weeks within 
treatment groups. Pearson’s coefficients ranged from 0.60 to 0.89 between subscales within each 
QoL instrument and from -0.61 to -0.21 across the instruments (p <.001). In the 5-FU group at 4 
weeks, the symptom and function subscales of Skindex and the social subscale of SCI were worse 
than their baselines (p <.001). In the vehicle cream group, the Skindex symptom and emotion sub-
scales and the SCI emotion subscale improved at 4 weeks (p <.001, p =.01, and .03, respectively). 
The mixed effects model analyses, accounting for the high correlations among subscales and for 
subject random effects, showed that the Skindex symptom subscale at 4 weeks changed most from 
baseline in response to topical 5-FU treatment, followed by the Skindex function subscale (p <.001). 
All Skindex and SCI subscales returned to baseline at 1 year. 5-FU toxicity scores based on images 
and patient-reported symptoms in the 5-FU group at 4 weeks were correlated with the two QoL 
instruments, and they improved after intervention. Both Skindex and SCI measured the temporary 
negative effects of topical 5-FU, but the symptom and function subscales of Skindex were more 
responsive to the treatment than SCI subscales.    
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Positive predictive value of the diagnostic code for hidradenitis suppurativa in an electronic 
database improves as number of codes increases
GE Kim,1 J Shlyankevich2 and AB Kimball1,2 1 Dermatology, Harvard Medical School, 
Boston, MA and 2 Clinical Unit for Research Trials and Outcomes in Skin, Massachusetts 
General Hospital, Boston, MA
Our goal was to validate the diagnosis of hidradenitis suppurativa (HS) in an electronic medical 
record database. The medical records of 1,168 patients who had received at least two International 
Classification of Disease, Ninth Revision 705.83 codes were manually screened and validated in 
chart review as having HS. The positive predictive value (PPV) was assessed by code frequency in 
1-, 2-, 3-, and 5-year windows. 1,046 (89.6%) patients were confirmed as having HS. The mean 
age (standard deviation) was 44.0 (15.7) years, median age was 43.0 years, and 71.5% of patients 
were female. The majority was white (66.7%), while a significant minority was black (13.9%) or 
Hispanic (13.4%). Higher PPV was associated with an increasing total number of codes, rising as 
high as 97.3% (95% confidence interval [CI]: 95.3, 98.6) for 5 or more codes. PPV of receiving 
a code from a dermatologist was 90.7% (95% CI: 87.4, 93.3) compared to a PPV of 89.0% (95% 
CI: 86.5, 91.1) for a non-dermatologist entered code. The PPV of having 2 codes or having 4 or 
more codes remained stable within both 1- to 5-year time periods at 82.1% (95% CI: 78.1, 85.6) 
to 83.2% (95% CI: 79.3, 86.6) and 97.0% (95% CI: 94.9, 98.4) to 96.6% (95% CI: 94.7, 97.9), 
respectively. Three codes in a 1-year time window had a PPV of 89.2% (95% CI: 83.5, 93.5) that 
decreased to 86.0% (95% CI: 80.2, 90.7) at 2 years and 86.2% (95% CI: 80.5, 90.8) at 5 years. 
Establishing the validity of diagnostic codes in electronic databases is a crucial step for subsequent 
studies utilizing these databases.    
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Patient-reported outcomes differ between psoriasis patients with clear and almost clear skin 
in the routine clinical practice setting: Results from the Dermatology Clinical Effectiveness 
Research Network
J Takeshita,1 KC Duffin,2 DB Shin,1 GG Krueger,2 AD Robertson,3 AB Troxel,1 AS Van 
Voorhees1 and JM Gelfand1 1 University of Pennsylvania, Philadelphia, PA, 2 University of 
Utah, Salt Lake City, UT and 3 National Psoriasis Foundation, Portland, OR
There is little evidence to guide the establishment of treatment goals for patients with moderate 
to severe psoriasis in the clinical setting. Psoriasis Area and Severity Index (PASI)-75 is the mostly 
widely used measure of clinical efficacy for psoriasis therapies. The proportion of patients with 
clear or almost clear skin based on Physician Global Assessment (PGA) is also increasingly used 
as a measure of clinical efficacy. It is uncertain if important differences exist between patients with 
clear and almost clear skin, especially from the patient perspective. The aim of this study was 
to determine if differences in the patient-reported Dermatology Life Quality Index (DLQI) score 
exist between psoriasis patients with clear and almost clear skin. We conducted a cross-sectional 
study of 538 patients with moderate to severe plaque psoriasis and with clear (PGA=0 or PASI=0) 
or almost clear (0<PGA<1.5 or 0<PASI<3) skin at 10 centers in the U.S. In unadjusted analyses, 
patients with clear skin reported a significantly lower median DLQI score (0; interquartile range, 
0-1) than patients with almost clear skin (2; 0-5; p<0.001). Patients with clear skin were more likely 
to not have used prescription topical medications in the preceding week compared to patients with 
almost clear skin (clear 22.7%; almost clear 65.5%; p<0.001). In adjusted analyses, patients with 
clear skin were more likely to report no effect (DLQI≤1) of psoriasis on their quality of life (QoL) 
than patients with almost clear skin (relative risk 1.60; 95% confidence interval, 1.37-1.86). Our 
results suggest that clearance of psoriasis abrogates the negative impact that active psoriasis has on 
a patient’s QoL and may be an important endpoint in the clinical setting.    
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Factors associated with being clear/almost clear of psoriasis in patients receiving adalimumab, 
etanercept, or methotrexate as part of routine clinical care
Y Hong,4 K Callis Duffin,2 J Takeshita,1 DB Shin,1 GG Krueger,2 AD Robertson,,3 AB Troxel,1 
AS Van Voorhees1 and JM Gelfand1 1 Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA, 2 School of Medicine, University of Utah, Salt Lake City, UT, 
3 The National Psoriasis Foundation, Portland, OR and 4 School of Public Health, Drexel 
University, Philadelphia, PA
While treatment options for psoriasis continue to expand, little is known about clinical factors that 
predict therapeutic response. Our goal was to identify which patient-related factors are associated 
with a favorable clinical response to therapy. We conducted a cross-sectional study of patients who 
were receiving adalimumab (N=148), etanercept (N=174), or methotrexate (N=163) for the primary 
indication of plaque psoriasis, evaluated in routine clinical care at 10 dermatology sites across the 
US. We assessed 38 clinical variables for their associations with being clear/almost clear of psoriasis. 
For the TNF inhibitors, having a normal or underweight body mass index was associated with an 
increased odds of being clear/almost clear compared to patients who were obese (adalimumab 
adjusted odds ratio [OR] 4.33; 95% confidence interval [CI], 1.64-11.47; and etanercept adjusted 
OR 2.79; 95% CI, 1.16-6.76). For methotrexate, women were more likely to be clear/almost clear 
compared to men (adjusted OR 3.29; 95% CI, 1.30-8.33). All other examined factors including 
age of psoriasis onset, psoriasis duration, total number of comorbidities, prior treatment history, 
psoriasis extent at its worst, and family history of psoriasis were not significantly associated with 
being clear/almost clear for any of these treatments. Our results indicate obesity to be associated 
with poor response to adalimumab and etanercept therapy, suggesting the need for weight based 
dosing of these biologics. We also found female sex to be the only clinical factor associated with a 
better response to methotrexate - a new finding that deserves further study.    
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Buying indoor UV tanning with university debit cards
LN Boyers,1 C Karimkhani,4 L Crane,5 N Asdigian,5 A Hollonds5 and R Dellavalle2,3,6 1 
Georgetown University School of Medicine, Washington, DC, 2 Dermatology, University of 
Colorado School of Medicine, Denver, CO, 3 Dermatology, Department of Veteran Affairs 
Denver, Denver, CO, 4 Columbia University College of Physicians and Surgeons, New York, 
NY, 5 Department of Community and Behavioral Health, Colorado School of Public Health, 
Denver, CO and 6 US Department of Veteran Affairs, Denver, CO
The booming indoor ultraviolet (UV) tanning industry in the United States is linked with morbid 
consequences; studies demonstrate the association between indoor tanning and skin cancer. This 
study determined the degree of affiliation between university debit cards and indoor UV tanning 
retailers. The two largest residential universities in each state were identified through Collegeboard.
org and web searches were conducted to obtain information regarding university debit cards. 
Eighteen of 96 (18.75%) universities listed indoor tanning merchants as retailers that accept their 
debit cards, with 11 listing more than one indoor tanning salon (range 1-8). Of note, universities 
linked with tanning salons were concentrated exclusively in the east and south of the United States. 
University agreements with tanning salons constitute endorsements of indoor tanning, which has 
been designated as a carcinogen by the World Health Organization. We call for all universities 
to limit the purchasing of indoor UV tanning and related products with university debit cards.   
291
Greater utilization of high-cost care settings by patients with hidradentitis suppurativa
J Kirby,1 JJ Miller1 and D Leslie2 1 Department of Dermatology, Penn State Hershey, Hershey, 
PA and 2 Department of Public Health Sciences, Penn State Hershey, Hershey, PA
The objective of this study is to assess how individuals with hidradenitis suppurativa (HS) utilize 
medical care in order to identify opportunities to improve the value and efficiency of care. A 
retrospective analysis of a medical claims database from 2008 to 2010 was performed to identify 
claims by patients with HS, psoriasis, and a control group of patients with neither condition. Direct 
costs were calculated as all-cause cost for the three-year period; patient and indirect costs were 
not included. Amounts are reported in 2010 US dollars and were adjusted for inflation. The largest 
component of the total 3-year cost for the HS group was inpatient cost (37.4%). In contrast, the 
largest component for the psoriasis group was drug costs (46.5%) and for the control group was 
inpatient costs (40.9%). The proportion of patients that utilized the emergency department (ED) 
over the 3-year period was higher in the HS cohort (27%) than the psoriasis (17%) or control groups 
(17%), (p<0.001). Similarly, the mean (SD) 3-year ED cost for the HS group was $2,002 ($6,632) and 
was higher than both comparison groups. After adjustment for age and gender, ED cost remained 
higher in the HS group (p<0.0001). The proportion of people in the HS cohort (16%) that were 
hospitalized was higher than the psoriasis (11%) or control (9%) groups (p<0.0001). Mean inpatient 
costs were similar for the 3 groups (p=0.99). One of the drivers of increased health care spending 
is the inappropriate use of high-cost care settings, such as inpatient and ED settings, for conditions 
such as HS that can be managed in an outpatient setting. High ED utilization by the HS cohort 
suggests that there is an opportunity to investigate the drivers behind ED utilization. Possible actions 
include timely communication with patients, ensuring outpatient access for acute disease flares, 
and educating providers and patients.    
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Representation of the top three most disabling skin diseases in the cochrane database of 
systematic reviews
C Karimkhani,1 LN Boyers,2 CA Dunnick3,4,5 and R Dellavalle3,4,5 1 Columbia University 
College of Physicians and Surgeons, New York, NY, 2 Georgetown University School of 
Medicine, Washington D.C., DC, 3 University of Colorado School of Medicine, Aurora, CO, 
4 Dept. of Veterans Affairs Medical Center, Denver, CO and 5 Colorado School of Public 
Health, Aurora, CO
The Global Burden of Disease (GBD) 2010 project established dermatitis, acne vulgaris, and bac-
terial skin diseases as the three most disabling skin conditions globally using the metric of disabili-
ty-adjusted life years (DALY). We sought to determine whether topics in The Cochrane Database of 
Systematic Reviews reflect this disease burden. Two investigators independently matched systematic 
review and protocol representation of 15 skin conditions studied by GBD in The Cochrane Data-
base of Systematic Reviews with their respective disability, measured in DALY metrics from GBD 
2010. All 15 skin conditions were represented by at least one systematic review in The Cochrane 
Database of Systematic Reviews. Dermatitis was well matched with the most reviews and protocols 
and highest disability. The next two most disabling diseases, acne vulgaris and bacterial skin dis-
eases, were under-represented. Similarly, urticaria, pruritus, scabies, cellulitis, and alopecia areata 
were under-represented while decubitus ulcer, psoriasis, and leprosy were over-represented when 
matched with corresponding disability estimates. Viral and fungal skin diseases, melanoma, and 
non-melanoma skin cancer were proportionately represented. Disease disability will influence 
future work priorities in The Cochrane Database of Systematic Reviews. Other factors influencing 
prioritization will include whether disease disproportionately affects disadvantaged populations, 
cost, availability and lack of cost-effective interventions, interest-group advocacy, disease trans-
missibility, public interest, opportunity for scientific innovation, and infrastructure building. Our 
results provide new transparent data to inform future prioritization decisions.    
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Langerhans cell histiocytosis and hematological malignancy: A Mayo Clinic experience
R Takahashi1 and M Pittelkow2 1 Medical Scientist Training Program, Mayo Clinic, 
Rochester, MN and 2 Dermatology, Mayo Clinic, Scottsdale, AZ
The goal of this study is to identify patients diagnosed with Langerhans cell histiocytosis (LCH) 
and determine the incidence of patients who had concurrent hematological malignancy. Due 
to the varied clinical course of LCH, there have been efforts to distinguish high-risk patients and 
predict disease progression based on organ system involvement. Previous studies have reported 
worse prognosis with involvement of ‘risk organs’ such as the hematopoietic system, however, the 
incidence of hematological malignancy in LCH patients is unknown. We identified 58 Mayo Clinic 
patient records with a final diagnosis of LCH (or equivalent term) and hematological malignancy. 
Review of paper and electronic medical records identified 19 patients with biopsy-proven LCH. 
13 of these patients (68%) had both biopsy-proven LCH and hematological malignancy. There 
were 6 males and 7 females with ages ranging from one to 81 years (median age of 53) at the time 
of LCH diagnosis. 5 of 13 patients were diagnosed with a hematological malignancy within one 
year of their LCH diagnosis. At least two patients had received chemotherapy, radiation therapy, 
or both. Hematological malignancies included acute myelogenous leukemia, non-Hodgkin’s and 
Hodgkin’s lymphoma, cutaneous T-cell lymphoma, hairy cell leukemia, multiple myeloma, and 
chronic myelomonocytic leukemia. We report a significant association of LCH with hematological 
malignancy. These findings suggest possible underlying shared mechanisms of clonal development 
of LCH and hematological malignancies and genomic instability or immune related mechanisms 
related to LCH that induce or facilitate leukemogenesis or lymphomagenesis. This study supports 
the need for regular ongoing surveillance as well as further investigation of secondary malignancies 
in patients with LCH.    
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Clinical manifestations in Behçet’s disease: A retrospective chart review
P Davari,1 RS Rogers2 and N Fazel1 1 Dermatology, University of California, Davis, 
Sacramento, CA and 2 Dermatology, Mayo Clinic, Scottsdale, AZ
Behçet’s disease is a chronic, inflammatory, vascular disorder of an unknown etiology. Its prevalence 
varies depending upon the geographic region and ethnicities. It can affect multiple organ systems 
including cardiac, neurologic and pulmonary. Delayed diagnosis and treatment can increase its 
morbidity and mortality rate. The literature is scarce on the clinical presentations of Behçet’s disease 
in the United States. The aim of this study is to determine the occurrence of clinical hallmarks in 
a cohort of 59 patient with a diagnosis of Behçet’s disease at the University of California, Davis. A 
retrospective chart review of the 59 patients was performed during a 10 year period (2003-2013). 
The International Criteria for Behçet’s Disease was utilized to include patients with a point score of 
five or more. Clinical features of the patients were collected, and the time order of manifestations 
was recorded, if possible. Mucocutaneous ulcers were the most common manifestation of the disease 
followed by articular and ocular involvement. Additionally, oral ulcers were the most common 
presenting sign of the disease followed by genital ulcers. These results paired with previous reports 
suggest that patients with oral and genital ulcers require close clinical surveillance for the appear-
ance of other clinical manifestations and possible evolution into Behçet’s disease.    
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The prevalence of pigmentary disorders among women in Shanghai, China is high
A Wuu,1 JL Chan,1 H Feetham,1 W Dai,3 T Duong,1 S Hollmig,1 LS Hynan2 and A Pandya1 1 
Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, 2 Departments 
of Clinical Sciences – Biostatistics and Psychiatry, University of Texas Southwestern Medical 
Center, Dallas, TX and 3 University of North Texas Health Science Center, Fort Worth, TX
Background: Disorders of pigmentation are common, but little is known about their prevalence. 
Objective: To determine the prevalence of pigmentary disorders among women in Shanghai, China 
Methods: A self-diagnostic tool was developed and validated in 82 Asian women. Subsequently, 
9000 women were approached in Shanghai, China, from which 600 women agreed to use the 
tool for self-diagnosis of pigmentary disorders. Results: The prevalence of lentigines, melasma and 
post-inflammatory hyperpigmentation was 41.7%, 18.5%, and 10.5%, respectively. Limitations: 
Generalizability of results is limited to Chinese women living in Shanghai. Conclusion: The prev-
alence of pigmentary disorders among women in Shanghai, China is high. The self-diagnostic tool 
developed in this study is reliable and valid for diagnosing pigmentary disorders in Asian women. 
Future studies should be performed with this tool to determine prevalence of these disorders in 
Asian women in other areas of the world.    
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Indoor air pollution from cooking with coal or firewood accelerates skin aging in northern 
Chinese women
A Vierkoetter,1 M Li,1,2 C Ma,3 B Deng,4 MS Matsui,5 J Krutmann1 and Z Li6 1 IUF-Leibniz 
Research Institute for Environmental Medicine, Duesseldorf, Germany, 2 CAS-MPG Partner 
Institute for Computational Biology, Shanghai, China, 3 Third Hospital of Peking University, 
Peking, China, 4 Estee Lauder Companies, Shanghai, China, 5 Estee Lauder Companies, 
Melville, NY and 6 Institute of Reproductive & Child Health of Peking University, Peking, 
China
Recently we showed that exposure to outdoor air pollution from traffic and industry is associated 
with an increased risk for skin aging in German women. In the present cross-sectional study we 
studied 403 Chinese women from 30 to 80 years old to assess the association between indoor air pol-
lution from cooking with coal or firewood and skin aging in Chinese women from a northern, rural 
area of China. Skin aging was evaluated by a validated tool, the SCINEXATM. Indoor air pollution 
exposure, sun exposure, smoking and other confounders were assessed by validated questionnaires. 
In adjusted linear and logistic regression analyses we tested the association between indoor air 
pollution and skin aging. We found that indoor air pollution was significantly associated with an 
increased appearance of wrinkles on the forehead (p=0.03), wrinkles under the eyes (p=0.002), and 
wrinkles on the upper lip (p=0.030), frown lines (p=0.006), depth of the nasolabial fold (p<0.001), 
telangiectasia (p<0.001), laxity of eyelids (p<0.001), cheek laxity (p=0.003), pigment spots on back 
of arms (p=0.003) and hands (p=0.003), uneven pigmentation on bottom side of the arm (p=0.039) 
and fine wrinkles on back of hands (p<0.001). Previously, in German women, we observed a 
significant increase in the nasolabial fold depth with an increase in outdoor air pollution, but also 
a pronounced increase of pigment spots on face, which we did not observe in the present study 
in Chinese women. The present study thus corroborates our previous finding that air pollution is 
associated with skin aging and extends it by showing that (i) indoor air pollution might be another 
risk factor for skin aging and that (ii) ethnic differences might influence the clinical manifestation 
of pollution-driven skin aging.    
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Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the 
Women’s Health Initiative (WHI)
MS Ally,1 A Wysong,1 C Gamba,2 S Swetter,1,2 M Stefanick2 and J Tang1 1 Dermatology, 
Stanford University, Redwood City, CA and 2 School of Medicine and Cancer Center, 
Stanford University, Stanford, CA
Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with a decreased risk of a variety 
of malignancies. However, data on the effect of NSAIDs on non-melanoma skin cancer (NMSC) 
risk are inconsistent. We prospectively examined whether regular NSAID or acetaminophen use is 
associated with a lower risk of NMSC in the Women’s Health Initiative (WHI) Observational Study 
(OS). Regular (use at baseline and year 3), inconsistent (use only at baseline or year 3), or no/low-use 
of NSAIDs (<2 times/week) was assessed among 54,728 postmenopausal Caucasian women aged 
50-79 years. Logistic regression models were used to assess odds of NMSC after adjusting for skin 
type, sun exposure history and indication for NSAID use among other confounders. During a median 
follow-up period of 6.9 years there were 7,652 incident cases of NMSC. There was no association 
between regular use of any NSAID and the risk of NMSC relative to no/low-users. However, in a 
subgroup analysis of 5,488 women with a history of skin cancer, relative to no/low users, odds of 
NMSC were lower among regular NSAID users whether <5 years (OR 0.82, 95% CI: 0.70-0.95) or ≥ 
5 years (OR 0.82, 95% CI: 0.69–0.98) of use. Inconsistent NSAID use and acetaminophen use were 
not associated with risk of NMSC. In women with a history of skin cancer, regular NSAID use was 
associated with 18% lower odds of NMSC. Further clinical studies are warranted to investigate the 
chemopreventative effects of NSAIDs in those at high risk for developing NMSC.    
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Female gender and acne disease are jointly and independently associated with the risk of 
major depression and suicide: A national population-based study
C Hong,1,2 Y Yang,3,4 H Tu,5 W Chang,6 H Fu,3,4 J Ho,3,4 H Chuang5 and C Lee3,4 1 
Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 2 Dermatology, 
National Yang-Ming University, Taipei, Taiwan, 3 Dermatology, Kaohsiung Chang Gung 
Memorial Hospital, Kaohsiung, Taiwan, 4 Dermatology, Chang Gung University, Taoyuan, 
Taiwan, 5 Kaohsiung Medical University, Kaohsiung, Taiwan and 6 Taipei Medical 
University, Taipei, Taiwan
Acne is a common disease in adolescence with female preponderance. It could cause poor self-es-
teem and social phobia. Previous studies based on questionnaires from several thousand adolescents 
showed that acne is associated with major depression and suicide. However, the gender- and 
age-specific risk of depression and suicide in patients with acne remains elusive. Using a database 
from National Health Insurance, which included 98% of population of Taiwan in 2006, we identified 
patients of acne, major depression, and suicide based on ICD-9-CM codes. Totally 47111 patients 
with acne were identified (16568 males and 30543 females) from 1 million subjects. The youths 
7-12 years had the highest prevalence of acne (14.39%). Major depression were more common in 
those with acne (0.77%) than controls (0.56%, p<0.0001) regardless of gender. Multiple logistic 
regression showed an increased risk to major depression in women without acne (OR=1.85, 95% CI 
1.75-1.96). The risk is additive in women with acne (OR=2.78, 95% CI 2.43-3.17). Similar additive 
risk of suicide was noticed in women with acne. In conclusion, acne and gender, independently 
and jointly, are associated with major depression and suicide. Special medical support should be 
warranted in females with acne for the risk of major depression and suicide.    
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The presence of T-cell clonality at presentation with mycosis fungoides is not influenced by 
patient gender or age
Y Balagula,1 S Dusza,2 JG Zampella,1 R Sweren1 and GA Hinds1 1 Dermatology, Johns 
Hopkins School of Medicine, Baltimore, MD and 2 Dermatology Service, Memorial Sloan-
Kettering Cancer Center, New York, NY
The presence of clonal rearrangement of the T-cell receptor gamma (TCR-gamma) chain gene by 
polymerase chain reaction may serve as an adjuvant tool in the diagnosis of Mycosis Fungoides (MF). 
Recent data suggest that the incidence and prognosis of MF differs between Caucasian and African 
American (AA) patients, and particularly AA women who present before age 40. Clonality differences 
between races and age groups at presentation have not been published. A retrospective analysis 
of patients with MF seen in the Johns Hopkins Dermatology Clinics in Baltimore, MD, from 2000 
to 2010 was performed with specific attention to gender, race, stage at presentation and clonality. 
A total of 312 patients, 209 Caucasian and 103 AA were identified. The mean age of Caucasian 
males, females and AA males and females was 55.5, 55.7, 47.4 and 44.4, respectively. Caucasian 
and AA patients presented with stage IA (n=105, 50.2% and n=31, 30.1%), IB (n=39, 18.7% and 
n=37, 35.9%), IIA (n=10, 4.8% and n=3, 2.9%), IIB (n=10, 4.8% and n=14, 13.6%), III (n=26, 
12.4% and n=7, 6.9%), IVA (n=15, 7.2% and n=8, 7.8%), and IVB (n=2, 1.0% and n=2, 1.9%), 
respectively. Clonality, when tested, was present among 68 (32.5%) and 29 (28.2%) Caucasian and 
AA patients, respectively (p=0.21). Similarly, clonality was detected in 21 (25.6%) and 76 (33.0%) 
patients younger and older than 40 years of age, respectively (p=0.24). The presence of clonality 
at presentation with MF does not appear to correlate with either the age or race of the patient.   
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Longitudinally followed nevi in children and adolescents show significant size changes
X Wu,1 M Fonseca,1 MA Marchetti,1 S Dusza,1 A Marghoob,1 AC Geller2 and AC Halpern1 
1 Memorial Sloan-Kettering Cancer Center, New York, NY and 2 Harvard School of Public 
Health, Boston, MA
While change in size is a recognized feature of melanoma, change in nevus size during childhood 
and adolescence is a part of normal growth. The objective of this study was to quantify the spectrum 
of size changes among existing and new nevi during childhood, stratified by dermoscopic pattern. 
The sample included a cohort of children in Framingham, Massachusetts, whose nevi were longi-
tudinally monitored between 5th and 11th grades. Study nevi were imaged at baseline and at each 
follow-up examination. These images, captured across different time points, were subsequently 
placed side-by-side for purposes of comparison. Nevus size was measured as surface area using a 
manual segmentation tool (Seg 3D). A total of 404 existing nevi in 136 children were followed from 
5th to 11th grade and a total of 121 new nevi in a subset of 92 children were followed from 8th or 
9th to 11th grade. Using a threshold of 50% or greater change in surface area, nevus size change 
in existing nevi differs significantly by dermoscopic pattern. 18% of reticular v.7% of globular nevi 
decreased in size while 52% of reticular v. 65% of globular nevi increased in size (p=0.02). These 
differences were even more pronounced for the subset of nevi (n=135) with the greatest area at 
baseline (top tertile) with 25% of reticular v. 1% of globular lesions decreasing in size and 33% of 
reticular v. 65% of globular lesions increasing in size (p=0.001). This trend was consistent across 
various followup time intervals. A similar trend was observed for new nevi with 36% of reticular v. 
48% of globular nevi increasing in size, while 11% of reticular v. 5% of globular nevi decreased in 
size (p=0.33). These findings demonstrate that nevi in children are dynamic, frequently manifesting 
size changes. The observation that globular nevi are more likely to increase in size than reticular 
nevi may reflect distinct biologic pathways in these subsets of nevi.    
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Hotspots of CTCL cases in Houston and Texas: A comparison of the MD Anderson and Texas 
cancer registries
I Litvinov,1 MT Tetzlaff,2 E Rahme,3 P Gangar,4 MA Jennings,2 D Risser,5 D Sasseville1 and 
M Duvic4 1 Dermatology, McGill University, Montreal, QC, Canada, 2 Pathology, The 
University of Texas MD Anderson Cancer Center, Houston, TX, 3 Clinical Epidemiology, 
McGill University, Montreal, QC, Canada, 4 Dermatology, The University of Texas MD 
Anderson Cancer Center, Houston, TX and 5 Cancer Epidemiology and Surveillance Branch, 
Texas Cancer Registry, Austin, TX
Cutaneous T-Cell Lymphoma (CTCL) is a rare cancer with a documented incidence of ~4-8 cases 
per million individuals per year. Currently, the pathogenesis of CTCL remains only partially under-
stood. Reports of incidence in married couples and families raise a possibility that there might be 
an important environmental trigger for this disease. However, to date no unequivocal geographic 
hotspots have been documented for this cancer. We analyzed by region, zip code, age and eth-
nicity the demographic data of 1047 patients from Texas, who were seen in a CTCL clinic at the 
MD Anderson Cancer Center (MDACC) during 2000-2012. In addition de-identified data on CTCL 
incidence was requested from the Texas Cancer Registry (TCR) database and similar analyses were 
performed on 1970 patients with MF and SS that were registered in that database between 1995-
2010. Subsequently both data sets were cross analyzed and compared. Our findings, based on the 
MDACC database results, document geographic clustering of patients in three communities within 
the Houston metropolitan area, in which the CTCL incidence rates were 10-50 times higher than 
the expected population rate. Moreover, analysis of incidence rates in these communities over time 
suggests a significant increase in the disease after ~2005. The data results from the TCR database 
defined the CTCL population rate for the state to be 5.57 [CI 5.34; 5.83] cases per million per year. 
Furthermore, the TCR database confirmed the above findings and highlighted 4 additional putative 
geographic hotspots for CTCL within the state of Texas, but outside the Houston metropolitan area. 
Identification of geographic clustering for CTCL argues for existence of yet unknown external causes 
in triggering this rare cancer.    
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Itch prevalence and characteristics in hispanic geriatric population: A comprehensive study 
using a validated itch questionnaire
R Valdes-Rodriguez,1 NK Mollanazar,1 J González-Muro,2 LA Nattkemper,1 B Torres-
Alvarez,2 T Gonzalez-Marquez,2 FJ López-Esqueda,3 Y Chan4 and G Yosipovitch1 1 
Dermatology - Temple Itch Center, Temple University School of Medicine, Philadelphia, 
PA, 2 Dermatology, Hospital Central “Dr. Ignacio Morones Prieto”, Universidad Autonoma 
de San Luis Potosi, San Luis Potosi, Mexico, 3 Geriatrics, Hospital Central “Dr. Ignacio 
Morones Prieto”, Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico and 
4 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore, 
Singapore, Singapore
Introduction: There is limited data regarding the prevalence and clinical characteristics of chronic 
itch in the elderly. Objectives: A comprehensive description of the prevalence and clinical char-
acteristics of pruritus affecting Hispanic geriatric subjects using a validated itch questionnaire. 
Methods: 302 geriatric patients without dementia were evaluated using a validated itch intensity 
and characteristic questionnaire. Patients were examined and assessed for itch-related dermatoses. 
Underlying systemic diseases were obtained from medical records. Results: Chronic itch was a 
common symptom experienced by 25% of subjects. Out of the patients who reported chronic itch, 
69% had xerosis, 28% had itch-related dermatoses and 96% had documented comorbidities. The 
most common comorbidities were Diabetes mellitus (DM) and chronic venous insufficiency (CVI). 
The most common areas where patients experienced itch were: legs (54%), back (45%), scalp (28%) 
and arms (27%). Patients reported experiencing the greatest amount of itch in the winter (77%) 
and during the night (65%). Conclusion: Chronic itch is a common problem in Hispanic geriatric 
population, with significant associations to dry skin, DM and CVI.    
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Feasibility, validity, and reliability of pediatric pruritus-specific outcome measures
A Ismail,1 J Fettig,2 K Chen3 and SC Chen3,4 1 University of Alabama Birmingham, 
Birmingham, AL, 2 Cleveland Clinic, Cleveland, OH, 3 Emory University, Atlanta, GA and 4 
Atlanta VA Medical Center, Atlanta, GA
Further development of pruritus-specific patient reported outcomes include two age-appropriate 
quality of life questionnaires: a cartoon version for ages 4-7 (TotsItchyQoL) and a text version for 
ages 8-17 (KidsItchyQoL). A cartoon-enhanced numeric rating severity scale (ItchyQuant) was also 
developed for pediatric use and for adults who may not be able to utilize the usual visual analog 
scale (VAS). In this study, we examined the reliability and feasibility of the pediatric ItchyQoL and 
ItchyQuant. Children with chronic itch (>6 weeks) were approached in dermatology clinic; consent-
ing patients completed the appropriate version of the ItchyQoL at baseline and two follow-up visits. 
The duration of the first time the survey was administered was measured to determine feasibility. 
Data from baseline and second administrations were used to test question items for reliability using 
Cronbach’s alpha coefficient (α, desired> 0.7) and for reproducibility using intraclass correlation 
coefficient (ICC, desired >0.7). To validate the ItchyQuant, we approached adult patients with 
chronic itch in dermatology clinic and had them complete both the usual VAS and the ItchyQuant, 
separated by a questionnaire. The Pearson Correlation Coefficient (r) was used to establish the 
strength of the linear relationship between the VAS and ItchyQuant values. Mean duration was 7 
minutes, 8 seconds for TotsItchyQoL (n=6) and 5 minutes, 23 seconds for KidsItchyQoL (n=19). 
Reliability and reproducibility were tested for the KidsItchyQoL (α=0.93, ICC=0.66, p=0.03) but 
could not be tested for TotsItchyQoL due to low number of subjects. 20 adult patients completed 
both the usual VAS and ItchyQuant, with r=0.88. Preliminary conclusions indicate feasibility (<8 
minutes) for the pediatric ItchyQoL instruments as well as excellent reliability and reproducibility in 
the older age group. Validity of the ItchyQuant is still unknown in children, but promising in adults.   
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Ethnic differences and environmental factors in skin aging
M Li,1,2 A Vierkoetter,2 A Ding,1 MS Matsui,3 B Deng,3 J Zhang,4 J Tan,4 Y Yang,4 
T Schikowski,2 L Jin,1,4 J Krutmann2 and S Wang1 1 CAS-MPG Partner Institute for 
Computational Biology, Shanghai, China, 2 Leibniz Research Institute for Environmental 
Medicine, Düsseldorf, Germany, 3 The Estee Lauder Companies Inc, Melville, NY and 4 
MOE Key Laboratory of Contemporary Anthropology, Fudan University, Shanghai, China
Environmental factors may interact with different genetic backgrounds to impact skin aging. In this 
study, we (i) compared ethnic differences in skin aging between Chinese and German women and 
(ii) explored environmental factors in both populations. Chinese and German women 65-90 years 
old were recruited and skin aging was assessed by the SCINEXATM. In adjusted regression analysis, 
we found that wrinkles under eyes (p<0.001), on upper lips (p=0.001) as well as laxity of eyelids 
(p=0.025) and cheeks (p<0.001) were more pronounced in Germans; while wrinkles on forehead 
(p<0.001) and nasolabial folds (p=0.002) were more pronounced in Chinese. Chinese showed 
larger pigment spots on forehead (p<0.001) and on cheeks (p<0.001); while Germans had larger 
number of pigment spots on arms (p<0.001) and hands (p=0.001). Skin aging signs were affected 
by environmental factors: sun exposure, smoking, alcohol consumption, education, pregnancy, use 
of contraception, and use of fossil fuels. Sun exposure had a more significant effect in Germans, 
affecting 12 skin aging signs, particularly signs related to pigment spots. In Chinese, indoor air 
pollution from cooking had a greater effect, affecting 7 skin aging signs. Cooking with fossil fuels 
primarily affected wrinkle related signs, including wrinkles on forehead (p<0.001), in the crow’s 
feet area (p=0.001), on upper lip (p<0.036) and nasolabial fold (p<0.001) as well as laxity of eyelids 
(p=0.007), laxity of cheeks (p=0.019) and fine wrinkles on hands (p=0.027). Our results confirm 
previous published findings that air pollution accelerates the appearance of skin aging symptoms. 
They also suggest that clinical manifestations of skin aging are modified by the type of pollution 
(indoor versus outdoor) as well as the ethnic background (Chinese versus Caucasian), indicating 
the existence of gene/environment interactions.    
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Adiponectin deficiency may cause decreased ATP synthesis and lower pH, leading to abnor-
mal muscle contraction and skin sensitivity in sensitive skin
E Kim,1,2,3 D Lee,1,2,3 Y Kim,1,2,3 M Kim,1,2,3 J Kim,1,2,3 K Kim,1,2,3 H Eun1,2,3 and J Chung1,2,3 
1 Department of Dermatology, Seoul National University College of Medicine, Seoul, 
Republic of Korea, 2 Laboratory of Cutaneous Aging Research, Biomedical Research Institute, 
Seoul National University Hospital, Seoul, Republic of Korea and 3 Institute of Human-
Environment Interface Biology, Seoul National University, Seoul, Republic of Korea
Sensitive skin represents hyperactive sensory symptoms showing exaggerated reactions in response 
to external irritants. Although sensitive skin is a very common condition affecting an estimated 50% 
of the population, its pathophysiology remains largely elusive. To investigate the pathogenesis of 
sensitive skin, healthy subjects with ‘sensitive’ or ‘non-sensitive’ skin were recruited based on 
standardized questionnaires and 10% lactic acid stinging test, and their skin samples were obtained 
following lactic acid or normal saline treatment. Subsequent transcriptome analysis revealed that 
genes involved in muscle contraction, carbohydrate and lipid metabolism, and ion transport and 
ionic balance were significantly decreased in sensitive skin. These altered genes could account for 
the abnormal muscle contraction, decreased ATP amount and lower pH observed in sensitive skin. 
In addition, pain-related transcripts such as TRPV1, ASIC3 and CGRP were significantly upregulated 
in sensitive skin, compared with non-sensitive skin. Interestingly, we also found that adiponectin 
(ADIPOQ) was significantly down-regulated in sensitive skin, and knockdown of ADIPOQ in RD 
cells could recapitulate the aforementioned gene signature and physiologic alterations in sensitive 
skin in vivo. On the other hand, treatment of RD cells with ADIPOQ reduced the expression of 
TRPV1, CGRP and ASIC3, which were increased by knockdown of ADIPOQ. Our findings suggest 
that ADIPOQ deficiency may play a critical role in the development of sensitive skin.    
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The epidemiology of concomitant hidradenitis and psoriasis: Experience of a tertiary care 
center
M Patel, J Cohen, J Lin, JF Merola, AA Qureshi and R Vleugels Dermatology, Brigham and 
Women’s Hospital, Boston, MA
Hidradenitis suppurativa (HS) and psoriasis (Ps) are chronic disorders in which common inflam-
matory pathways including IL-12, IL-23, and TNF-α have been implicated. Currently, limited data 
exists on the co-occurrence of these two conditions; we therefore sought to describe the charac-
teristics of individuals with concomitant HS and Ps, seen at a tertiary care center. We conducted 
a retrospective analysis of all medical records within the Research Patient Data Repository . We 
identified 56 individuals with a diagnosis of both HS and Ps made by a board-certified dermatologist 
at Brigham and Women’s Hospital between January 2000 and June 2010. Of these 56 patients, 84% 
were female, 70.1% were white, 14.0% were black, 8.8% were Hispanic, and 3.5% were Asian. 
We also matched 169 controls for gender, age, and race. The mean BMI for patients with both HS 
and Ps was 34.1, compared to 27.1 in the control group (p<0.001). Hypertension was diagnosed or 
treated in 46.4% of patients with HS and Ps compared to 15.5% of the controls (p<0.001). Diabetes 
mellitus was diagnosed or treated in 23.3% of patients with HS and Ps compared to 7.7 % of the 
controls (p=0.002). Additionally, 14.3% of patients with both HS and Ps had inflammatory bowel 
disease, compared to 1.4% of patients in the control group (p<0.001). Overall, 39.3% of individu-
als with HS and Ps were current smokers, compared to 13.1% of the controls (p<0.001). Notably, 
we found that 40.4% of individuals with both HS and Ps had been diagnosed with and/or treated 
for depression compared to 19.0% of the controls (p<0.001). The psoriasis sub-types among the 
HS and Ps patients mirrored the distribution observed in the general psoriasis population. In this 
study, we describe a group of individuals with concomitant HS and psoriasis, in which we found 
a predominance of women, significantly elevated BMI, higher proportion of current smokers, and 
high rates of hypertension, diabetes, inflammatory bowel disease, and depression.    
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Sildenafil use and increased risk of incident melanoma in US men: A prospective cohort study
W Li,1 A Qureshi,1 K Robinson2 and J Han1 1 BWH, Harvard Medical School, Boston, MA 
and 2 MGH, Harvard Medical School, Boston, MA
Background: The RAS/RAF/MEK/ERK cascade plays a crucial role in melanoma cell proliferation and 
survival. Sildenafil (Viagra) is a phosphodiesterase (PDE) 5A inhibitor commonly used for erectile 
dysfunction. Recent studies have shown that BRAF activation down-regulates PDE5A levels, and 
low PDE5A expression by BRAF activation or sildenafil use increases the invasiveness of melanoma 
cells, which raises the possible adverse effect of sildenafil use on melanoma risk. Objective: To 
evaluate the association between sildenafil use and risk of incident melanoma among men in 
the US in a prospective cohort study. Methods: In 2000, participants in the Health Professionals’ 
Follow-up Study were inquired regarding sildenafil use for erectile dysfunction. Participants who 
reported cancers at baseline were excluded. A total of 25,848 men remained. Incidence of skin 
cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) 
was obtained in the self-reported questionnaires biennially. The diagnosis of melanoma and SCC 
was pathologically confirmed. Results: We identified 142 melanoma, 580 SCC, and 3,030 BCC 
cases during the follow-up (2000-2010). Sildenafil recent use at baseline was significantly associated 
with an increased risk of subsequent melanoma with a multivariate-adjusted hazard ratio (HR) of 
1.84 (95% confidence interval (CI):1.04-3.22). In contrast, we did not observe an increase in risk of 
SCC (HR=0.84, 95%CI:0.59-1.20), or BCC (HR=1.08, 95%CI:0.93-1.25) associated with sildenafil 
use. Moreover, erectile function itself was not associated with an altered risk of melanoma. Ever 
use of sildenafil was also associated with a higher risk of melanoma (HR=1.92; 95%CI:1.14-3.22). 
A secondary analysis which excluded those reporting major chronic diseases at baseline did not 
appreciably change the findings; the HR (95% CI) of melanoma was 2.24(1.05-4.78) for sildenafil 
use at baseline and 2.77(1.32-5.85) for sildenafil ever use. Conclusions: Sildenafil use may be 
associated with an increased risk of developing melanoma.    
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Non-melanoma skin cancer is associated with increased risk of fractures
E Anderson,1 M Stefanick,2 M Desai,3 J Kubo,3 A Wysong1 and J Tang1 1 Dermatology, 
Stanford University School of Medicine, Stanford, CA, 2 Stanford Prevention Research 
Center, Stanford University School of Medicine, Stanford, CA and 3 Quantitative Sciences 
Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA
Patients with NMSC have been shown to have lower vitamin D levels due to sun avoidance and 
protection. Low vitamin D levels can lead to fractures. We assessed whether post-menopausal 
women with a history of NMSC have an increased risk of fractures in a prospective cohort study of 
73,645 women from the Women’s Health Initiative. We followed 4,289 women with NMSC and 
67,470 without history of NMSC for 10 years for new hip, spine, and lower arm fractures. Women 
with prior history of fracture, systemic steroid use, hip replacement, and new skin cancer during 
follow-up were excluded. Hazard ratios (HR) and 95% confidence intervals (CI) were computed 
from Cox proportional hazards models. In age-adjusted models, women with history of NMSC had 
a higher risk of hip (HR 1.55, 1.31-1.85 95% CI, P<0.0001), spine (1.29, 1.10-1.51, P=0.0018), and 
lower arm (1.28, 1.13-1.45, P<0.0001) fracture. In models adjusted for sun exposure, sun screen 
use, vitamin D intake, physical activity, and other risk factors for fractures, only lower arm fracture 
remained statistically significantly associated with NMSC (HR 1.16, 1.31-1.85 95% CI, P=0.022) 
with hip fracture trending toward significance (1.18, 0.99-1.41, 0.06). A subset of women (N=4,267) 
had bone marrow density (BMD) scans, and there was no association between history of NMSC 
and hip BMD at baseline. These results suggest that prior history of NMSC is associated with an 
increased risk of subsequent bone fracture, contrary to our hypothesis. Increased fracture risk may 
be secondary to sun avoidance after NMSC diagnosis.    
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Health care utilization prior to diagnosis as a predictor of melanoma-specific mortality
MJ Eide,1,2 G Jacobsen,2 R Krajenta2 and CC Johnson2 1 Derm, Henry Ford Health System, 
Detroit, MI and 2 Pub Health Sci, Henry Ford Health System, Detroit, MI
The objective of this study was to examine the relationship of melanoma-specific mortality with 
pre-diagnosis health care utilization and preventive care compliance in a large health maintenance 
organization (HMO), where all enrollees would have presumable opportunity and equal access for 
receipt of care. A retrospective observational cohort of individuals from 2001-2007 was identified 
using the electronic HMO administrative databases, including information on patient demographics, 
US Census socioeconomic estimates, and healthcare utilization. Cutaneous malignant melanoma 
diagnosis and vital status were ascertained from the HMO Tumor Registry and the corresponding 
SEER Registry. Multivariate Cox regression estimates were calculated. 251 patients were identified 
with a mean age of 60.6 years. The majority of patients were white (96%), male (63%), and had 
localized disease (63%). Melanoma-specific mortality was significantly decreased in those who had 
a screening lipid panel (unadj HR 0.3 (0.1-0.9)) or colonoscopy screening prior to diagnosis (unadj 
HR 0.3 (0.1-0.8)). Having at least 1 primary care outpatient visit in the 5 years prior to diagnosis was 
associated with a 70% reduction in melanoma-specific mortality (unadj HR 0.3 (0.1, 0.9) as was an 
outpatient specialty visit in the five years prior to diagnosis (unadj HR 0.3 (0.1, 0.8). Controlling for 
age, gender, SES, and co-morbidities, outpatient visits to specialists pre-diagnosis were associated 
with a more than a 90% reduction in melanoma-specific mortality (adj HR 0.1 (0.0, 0.4)). Access 
to care does not equate to utilization. This study is important in that it demonstrates that utilization 
of care may translate to reduced melanoma-specific mortality regardless of demographic, socio-
economic or other comorbid medical factors. As the US begins a period of increased healthcare 
access, it is imperative that public health messages continue to encourage appropriate utilization.   
310
Adults with previous nonmelanoma skin cancer still suffer from sunburns despite improve-
ments in sun-protection practices
AH Fischer, AL Chien, T Wang and S Kang Dermatology, Johns Hopkins, Baltimore, MD
Previous nonmelanoma skin cancer (NMSC) is highly associated with increased risk of subsequent 
skin cancer. Thus, it is important for adults with previous NMSC to limit UV radiation (e.g., sun 
exposure), a known risk factor for NMSC. However, it is unclear whether individuals with a history 
of NMSC engage in better sun protection compared to those with no skin cancer history. We used 
self-reported data from US non-Hispanic white adults from the 2000, 2005, and 2010 Centers for 
Disease Control and Prevention (CDC) National Health Interview Surveys (54663 reporting no 
history of skin cancer, 1099 reporting previous NMSC). We calculated odds ratios (OR) and 95% 
confidence intervals (95%CI) using logistic regression, taking into account the complex survey 
design and controlling for age, sex, geographic region, skin type, education, and family history of 
skin cancer. We found that subjects with previous NMSC were significantly more likely than subjects 
with no history of skin cancer to apply sunscreen (OR=2.26; 95%CI=1.86-2.74; p<0.0001), wear 
long sleeves (OR=1.45; 95%CI=1.23-1.70; p<0.0001), and wear a wide-brimmed hat (OR=1.70; 
95%CI=1.45-1.98; p<0.0001) on a warm sunny day. However, previous NMSC was not signifi-
cantly associated with a decrease in recent sunburn (OR=0.91; 95%CI=0.75-1.10; p=0.32). Among 
subjects with previous NMSC, 30% reported recent sunburn. This subgroup was more likely than 
subjects without recent sunburn to be male (OR=1.57; 95%CI=1.10-2.23; p=0.01) and younger (ORs 
of 1.00, 0.58, 0.35, and 0.13 for subjects 18-50, 51-60, 61-70, and 71+ years of age, respectively; 
p-value for linear trend <0.0001). Subjects with previous NMSC report more consistent sun-protec-
tion practices, suggesting that they understand the benefits of UV protection. However, a substantial 
percentage of these individuals still report recent sunburn, especially among men and younger 
subjects. These findings suggest the need for more effective patient education, even in those with 
previous NMSC, on proper methods of sun protection to minimize UV exposure.    
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Sleep disordered breathing and risk of incident psoriasis in US women
JM Cohen,1 CL Jackson,3 T Li1,2 and A Qureshi1,2 1 Department of Dermatology, Brigham and 
Women’s Hospital; Harvard Medical School, Boston, MA, 2 Channing Laboratory, Brigham 
and Women’s Hospital, Boston, MA and 3 Harvard School of Public Health, Boston, MA
Sleep disordered breathing (SDB), including obstructive sleep apnea and snoring, and psoriasis have 
been associated with poor health outcomes such as diabetes mellitus and cardiovascular disease and 
reduced quality of life. The presumed mechanism of these associations is systemic inflammation. We 
evaluated the association between SDB and incident psoriasis and psoriatic arthritis (PsA) in a large 
cohort of US women. Participants received follow-up questionnaires every two years and were asked 
about snoring, diagnosis of sleep apnea, and diagnosis of psoriasis and PsA. We studied individuals 
who reported data on snoring and sleep apnea prior to diagnosis with psoriasis or PsA. When asked 
if they snored, participants were broken into five categories: never snore, occasionally snore, snore 
a few nights per week, snore most nights, and snore every night. We used Cox proportional hazards 
to calculate age-adjusted and multivariate risk ratios. Women with sleep apnea were more likely to 
have a higher BMI, be hypertensive, work night shifts, and have type 2 diabetes mellitus. Sleep apnea 
was associated with an increased risk of incident psoriasis in age-adjusted (relative risk (RR) 2.24 
(95% confidence interval (CI) 1.50-3.34)) and multivariate models (RR 2.04 (95% CI 1.35-3.07)). 
We further adjusted for night shift work and found no material change in relative risk (RR 2.02 
(95% CI 1.34-3.05)). There was no effect modification by BMI (p=0.65) or hypertension (p=0.42). 
Sleep apnea was not associated with an increased risk of incident PsA. Although women with sleep 
apnea were more likely to be snorers, we did not find a statistically significant relationship between 
snoring and the risk of confirmed incident psoriasis. We found that sleep apnea was associated with 
a greater than 2-fold risk of psoriasis among US women.    
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Psoriasis patient preferences for health-related benefit-risk tradeoffs using choice-format 
conjoint analysis
AW Armstrong,1 J Wu2 and E Brezinski2 1 University of Colorado Denver, Aurora, CO and 2 
University of California Davis, Sacramento, CA
Despite advances in new psoriasis treatments, weighing substantial therapeutic benefit against risks 
is important for clinicians, patients, and other stakeholders. Determining stakeholder preferences 
regarding benefit-risk tradeoffs is paramount for deciding whether to use certain medications in indi-
vidual patients. We aimed to determine health-related benefit-risk tradeoffs in a non-expected-utility 
framework using conjoint analysis among psoriasis patients. We administered choice-format, con-
joint surveys to 120 psoriasis patients with moderate-to-severe psoriasis and obtained preference 
data on treatment benefits and risks. The patients were asked to evaluate treatment options based 
on the following attributes—magnitude of psoriasis symptom reduction (at least 75% reduction from 
baseline psoriasis severity), time to initial response, time to maximal response, and durability of 
response. Serious adverse events were defined as 10-year mortality risks for two possible categories 
of adverse effects: serious infections (such as tuberculosis) and malignancies excluding non-mel-
anoma skin cancers. We analyzed the data using conditional-logit model and compared several 
model specifications. We also estimated the utility losses associated with adverse-event risks. Based 
on the rank-dependent expected utility model with the Tversky and Kahneman function, we found 
that the maximum acceptable 10-year adverse event risks for improved psoriasis outcomes was 
3.57% for serious infections and 1.82% for malignancies excluding non-melanoma skin cancers. We 
found that, in the psoriasis population, risk preferences are different depending on risk type and that 
quantitative benefit-risk analysis need to account for the probability weighting of patient preferences.   
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Development of a geographically-adjusted tool to more accurately estimate self-reported 
cumulative ultraviolet exposure: A two-part study
G Zhu, A Li and AS Chang Dermatology, Stanford University School of Medicine, Redwood 
City, CA
Accurate estimation of cumulative lifetime ultraviolet (UV) exposure is critical as it is a major risk 
factor for cutaneous cancers and diseases. However, current survey methods of self-reporting lifetime 
UV exposure rely on duration of time outdoors without accounting for differences in ambient UV 
irradiance levels in different locales. The purpose of this study was to pilot a method to incorporate 
geographic-specific ambient UV indices into current methods of estimating lifetime sun exposure. 
The first part of this study was development of a 23-item survey instrument enabling incorporation 
of multi-year averages of UV indices from the United States National Weather Service. The second 
part of the study was an IRB-approved test of the survey instrument in a cohort of 35 adult female 
volunteers who were part of ongoing skin aging study at Stanford University. After accounting 
for geographic locations resided, there was a significant difference in cumulative UV irradiance 
levels in individuals who had lived in one state (e.g. California) ≤85% of their lives (n=12) com-
pared to those who had lived outside of California >85% of their lives (n=23), hours*mean UV 
Index Units=298,075 (S.D.=207,221) vs. 525,056 (S.D.=244,751) respectively, p=0.007. Without 
accounting for geographic locations resided, the difference in cumulative lifetime UV exposure in 
these two groups was less significant. The improved performance of our novel measure is due to the 
ability to detect a faster rate of UV dose accumulation hour-for-hour among individuals who had 
lived >85% of their lives in California compared to those who did not, mean UV Index Units = 5.77 
(0.14) vs. 5.19 (0.51), p < 0.001. This tool can be applied to states other than California, and may 
be highly useful in regression analyses to more accurately account for cumulative lifetime sun expo-
sures, a critical element for clinical research in skin diseases associated with ultraviolet exposures.   
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Lupus patients with cutaneous hypersensitivity to hydroxychloroquine may tolerate 
chloroquine
AN Femia,1,2 JF Merola2 and R Vleugels2 1 Ronald O. Perelman Dept. of Dermatology, NYU 
Medical Center, New York, NY and 2 Dept. of Dermatology, Brigham & Women’s Hospital, 
Harvard Medical School, Boston, MA
The antimalarials hydroxychloroquine (HCQ) and chloroquine (CQ) are first-line therapy for sys-
temic and cutaneous lupus erythematosus (SLE and CLE). HCQ is generally used initially, with CQ 
reserved for patients who fail to tolerate or improve with HCQ. Roughly 10% of patients develop 
a cutaneous hypersensitivity reaction to HCQ. No study evaluates the potential of cross-reaction 
with CQ in SLE/CLE patients who react to HCQ. Using retrospective chart review from the Partners 
Healthcare Research Patient Data Registry, we identified 5 SLE/CLE patients with hypersensitivity 
to HCQ who subsequently tolerated CQ. Patients were aged 20-58 years old, 4 were female and 
1 male, and all had SLE and/or CLE. Three patients developed a morbilliform eruption 3-4 weeks 
into therapy with HCQ, 1 patient developed a morbilliform eruption after 3 months of HCQ ther-
apy, and 1 patient developed a pruritic eruption 32 months after initiation of HCQ. All cutaneous 
eruptions resolved with discontinuation of HCQ. The patient who developed a reaction 32 months 
into therapy was re-challenged with HCQ with recurrence of the pruritic eruption. All 5 patients 
tolerated transition to CQ without evidence of a hypersensitivity reaction. One patient discontinued 
CQ after 6 weeks due to potential drug interaction, and another after 4 weeks due to nausea. The 
additional 3 patients have remained on CQ for a range of 4-22 months. Importantly, no patient 
identified in this review who developed a cutaneous hypersensitivity eruption to HCQ and transi-
tioned to CQ went on to develop a similar reaction to CQ. This review supports the notion that CQ 
can be tolerated in lupus patients who develop hypersensitivity to HCQ, an important finding given 
the benefits of antimalarial therapy in patients with lupus, and the lack of alternative medications 
with analogous effects and comparable low side-effect profiles. Further studies are necessary to 
elucidate these findings.    
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Dermoscopic patterns of nevi have a distinct anatomical distribution in adolescents
M Fonseca,1 M Burnett,1 S Dusza,1 M Marchetti,1 A Geller,2 A Marghoob1 and A Halpern1 1 
Dermatology, Memorial Sloan-Kettering Cancer Center, New York, NY and 2 Harvard School 
of Public Health, Boston, MA
Nevi with a reticular versus globular dermoscopic pattern are hypothesized to represent distinct 
biologic subsets of nevi that differ in etiology, anatomic distribution, and association with sun 
exposure and phenotype. The purpose of this study was to describe the prevalence of dermoscopic 
patterns of nevi on the legs and backs of adolescents and to investigate the relationship between 
phenotypic characteristics and dermoscopic pattern. Overview and dermoscopic images of nevi 
were obtained from the back and legs of 213 9th graders (mean age 14.9 yrs). Nevi were classified 
as reticular, globular, homogenous (neither reticulation nor globules were present) or complex (both 
network and globules were observed). Compared to homogeneous lesions, globular nevi were more 
commonly observed on the back than the legs (OR=4.8; 95% CI: 2.4-9.7), while reticular nevi were 
less likely to be observed on the back than the legs (OR=0.7; 95% CI: 0.5-0.9). Participants with 
darker phenotypes were more likely to have reticular and complex lesions when compared to lighter 
phenotypes (OR=1.5, 95% CI: 1.1-2.0; OR=3.1, 95% CI: 1.8-5.4). Based on our results, we con-
clude that the dermoscopic patterns of nevi correlate with anatomic location in adolescents. More 
specifically, globular nevi have a cephalad to caudal distribution, which happens to recapitulate 
the pattern of melanoblast migration during embryogenesis. In contrast, the predominant pattern 
of nevi on the legs is reticular. These data suggest that globular and reticular nevi represent distinct 
subsets of nevi with different causal pathways and associations with sun exposure and phenotype. 
This in turn may help inform us about the pathways of melanomagenesis.    
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Patterns of dermatological changes due to chemotherapy and its impact on quality of life 
among breast cancer patients
D Kang,1 J Cho,1,2 E Choi,2 I Kim,2 D Lee,3 W Gil,4 J Lee4 and S Nam4 1 Health Sciences 
and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea, 2 Cancer 
Education Center, Samsung Medical Center, Seoul, Republic of Korea, 3 Dermatology, 
Samsung Medical Center, Seoul, Republic of Korea and 4 Surgery, Samsung Medical Center, 
Seoul, Republic of Korea
Background: The study aimed to evaluate dermatological side effects of chemotherapy (Doxorubi-
cin, Cyclophosphamide, and 5-Fluorouracil) and its impact onquality of life among breast cancer 
patients. Methods:This is a prospective cohort study with 81 breast cancer patients. Dryness and pig-
mentation on skin of face and hands were measured using Corneometer, Subumeter, Mexameter and 
Vapometer before, during, 1 month, 3 months, and 6 months after chemotherapy, and quality of life 
was assessed using Dermatology Life Quality Index (DLQI) and EORTC-QLQ C 30. Results:Patients 
with chemotherapy (n=61, 75.3%) experiencedsignificantly more dryness and pigmentation during 
chemotherapycompared to the baseline and it did not recovered even 6 months after completion of 
chemotherapy. About 70% of patients reported difficulties due to dermatological change (DLQI>2). 
More dryness and pigmentation patients experienced more physical symptoms (p<0.01) and dif-
ficulties with leisure activities (p<0.01) were reported. Some patients(23.7%) have problemswith 
personal relationships because of the skin changes. Patients with poor dermatological quality of 
life (DLQI>2) had lower physical (P<0.01), emotional (P<0.01), role functions (P<0.01), and body 
image (P<0.01) compared to those who had DLQI≤2 adjusting all other factors. However, only 
44.1 % of patients took care of theirskin during chemotherapy. Conclusions:Breast cancer patients 
experience difficulties of daily activities due to chemotherapy-induced dryness and pigmentation 
resulting in low quality of life. Health professionals need to monitor dermatological changes during 
chemotherapy and provide appropriate supportive care.    
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Development and validation of chemotherapy-induced dermatology distress scale
J Cho,1,2 D Kang,1 E Choi,2 I Kim,2 J Yoon2 and S Park1 1 Health Sciences and Technology, 
SAIHST, Sungkyunkwan University, Seoul, Republic of Korea and 2 Cancer Education 
Center, Samsung Medical Center, Seoul, Republic of Korea
Background: Although skin problems among cancer patients were usually perceived as minor 
complaints by health professionals, patients reported distress and difficulties due to chemotherapy 
induced skin changes such as dryness and pigmentation. However, few studies investigated this 
issue, and even no validated instrument to assess chemotherapy induced dermatology distress 
existed. The aim of this study was developed and validated a psychometric scale for assessing the 
distress that cancer patients experience due to chemotherapy-induced skin changes. Methods: 
Twenty-five items in 5 domains was developed for assessing chemotherapy-induced dermatology 
distress based on a qualitative study. To extract factor structure and evaluate construct valid, a 
cross-sectional survey was conducted with 345 Korean women with breast cancer and exploratory 
and confirmatory factor analysis were performed. Results: Exploratory factor analysis indicated 
that10 items contributed to three domains. Two items loaded to ‘physical’, and each of four items 
loaded to ‘body image’ and ‘emotional’. In confirmatory factor analysis, the model fit was good 
(CFI=0.97).Coefficient alphas ranged from 0.76 to 0.92 for sub-domains and 0.92 for total. The 
mean score of CDDS in the study population was 22.2 (SD=7.14) and patients who experience skin 
dryness and color change reported significantly higher CDDS scores compared to people without 
skin changes. The CDDS was moderately correlated with body image (r=-0.67, P<0.001), overall 
quality of life (r=-0.45, P<0.001), and self-esteem (r=-0.37, P<0.001). Conclusions: Our study con-
firmed that the CDDS is a reliable and valid tool for measuring distress of chemotherapy-induced 
skin change. The CDDS would help health professionals to assess and monitor distress that cancer 
patients could experience due to chemotherapy-induced skin changes.    
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Increased risk of incident depression in psoriasis patients
E Dommasch,1 T Li,2 Y Li3 and AA Qureshi2,4 1 Dermatology, Boston University School of 
Medicine, Boston Medical Center, Boston, MA, 2 Medicine, Channing Laboratory, Brigham 
and Women’s Hospital, Harvard Medical School, Boston, MA, 3 Nutrition, Harvard School 
of Public Health, Boston, MA and 4 Dermatology, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA
An association between psoriasis and mental health disorders has long been suspected. Recent 
cross-sectional studies have described links between psoriasis and depression. In this prospective 
study, we investigated the risk of incident depression among individuals with psoriasis. The study 
population consisted of two separate longitudinal cohorts, including 50,750 US female nurses in the 
Nurses Health Study I (NHS I) (mean age = 65.6 years) and 18,079 male health professionals in the 
Health Professionals Follow-Up Study (HPFS) (mean age = 67 years), who were free of depression 
at baseline. Participants had reported whether they had ever been diagnosed as having psoriasis. 
We defined depression as self-report of diagnosis of depression and regular use of antidepressant 
medication. Baseline year was the first year participants reported whether they had ever had a 
diagnosis of depression, and those with self-report of depression or use of antidepressant medi-
cation were excluded. In NHSI, those with Mental Health Index score <52 were also excluded. 
Among individuals with psoriasis, in NHSI, there were 58 incident cases of depression across 1969 
person-years (PYs) of follow-up from 2000-2008. There were 46 incident cases over 4383 PYs in 
the HPFS from 2002-2008. We found an increased multivariate relative risk (RR) of depression of 
1.33 (95% confidence interval (CI): 1.02, 1.73) in NHSI and 1.58 (95% CI: 1.17, 2.13) in HPFS, 
compared to participants without psoriasis. When looking at antidepressant medication use alone 
as the outcome, this risk was attenuated, with multivariate RRs of 1.30 (95% CI: 1.09,1.56) for NHSI 
and 1.22 (95% CI: 0.96, 1.54) for HPFS. This study supports an increased incident risk of depression 
among US women and men with psoriasis.    
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Healthcare utilization and cost in US adults with eczema
J Silverberg and N Garg Dermatology, Northwestern University, Chicago, IL
Little is known about the public health burden of adult eczema in the US. The goal of this study 
was to determine the out-of-pocket costs, healthcare access and utilization in adult eczema in the 
US. We used the 2010 National Health Interview Survey from a nationally representative sample of 
27,157 adults age 18–85 years. Adults with eczema and eczema with asthma and/or hay fever (EAH) 
had $1,497 and $1,800 per person-year compared with $1,298 in those without eczema. Adults 
with eczema and EAH were significantly more likely to have ≥6 lost workdays (survey multinomial 
logistic regression; adjusted odds ratio [95% confidence interval] for eczema: 1.48 [1.19–1.84]; 
EAH: 1.78 [1.34–2.36]) and 3-5 (eczema: 1.49 [1.21–1.83]; EAH: 2.06 [1.53–2.76]) and ≥6 days 
(eczema: 1.72 [1.41–2.08]; EAH: 3.69 [2.91–4.69]) days in bed compared with no eczema. Adults 
with eczema and/or EAH had significantly increased odds of doctor visits, urgent care or emergency 
department visits, homecare visits and hospitalizations. Adults with eczema and EAH were more 
likely to report being unable to afford prescription medications (aOR [95% CI] for eczema: 1.49 
[1.24–1.80]; EAH: 2.50 [1.98–3.14]) and having delayed care (eczema: 1.45 [1.22–1.71]; EAH: 
2.07 [1.63–2.62]) and not being able to get care (eczema: 1.34 [1.11–1.62]; EAH: 2.24 [1.70–2.94]) 
because of worry about the related costs. This study provides US population-based estimates of 
the public health burden of eczema in adults. The results suggest substantial out-of-pocket costs, 
indirect costs from lost work and sick days and increased healthcare utilization.    
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Existing self-report tools are not suitable for measuring adherence to topical therapies in 
psoriasis
RJ Thorneloe,1 P Nelson,1 C Bundy,1 CE Griffiths,1 DM Ashcroft2 and L Cordingley1 1 Centre 
for Dermatology Research, Institute of Inflammation and Repair, University of Manchester, 
Manchester Academic Health Science Centre, Manchester, United Kingdom and 2 School of 
Pharmacy, University of Manchester, Manchester, United Kingdom
Adherence to topical therapies is poor in patients with psoriasis however the use of non-validated 
self-report tools in studies limits conclusions. Validated self-report tools such as the Medication 
Adherence Report Scale (MARS) are widely used to estimate adherence to oral medicines, however 
their validity for measuring adherence to topical therapies is unknown. Using in-depth cognitive 
interviews, the suitability of the MARS for measuring adherence to topical therapies was examined 
in 20 psoriasis patients recruited from UK community samples. Patients completed the MARS whilst 
simultaneously providing reasons for responses using a think-aloud technique. Data were coded and 
themes identified using content and framework analysis. As topical treatment prescription advice 
can vary more than oral medication, participants reported high levels of uncertainty about both 
quantity and frequency of treatment application. Patients made strategic judgements about their 
use of topical treatment which they had not discussed with clinicians. Strategies included either 
intentionally reducing or increasing the volume of medication used or the frequency of application, 
however this variable adherence was not reflected in the corresponding MARS scores. The thematic 
analysis of interview data identified the following influences on these behaviours: a) patients’ own 
beliefs about the cause of flares; b) perceived efficacy of topical therapies; and c) high levels of 
emotional distress. In its current form the MARS was unable to identify intentional non-adherence 
(neither over- or under-use of treatments). Given that most patients with psoriasis are managed with 
topical therapy and progression onto systemic therapy is largely determined by treatment response, 
a brief, valid and reliable tool for measuring adherence variability to topical treatments in both 
research and clinical settings is warranted.    
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Melanoma thickness and survival trends in the United States, 1989 to 2009
WR Shaikh,1,2 SW Dusza,1 SA Oliveria,1 AC Geller,3 AC Halpern1 and MA Weinstock2 1 
Memorial Sloan-Kettering Cancer Center, NY, NY, 2 Brown Univ., Providence, RI and 3 
Harvard Univ., Boston, MA
With melanoma incidence rising and mortality stable some question whether the melanoma epi-
demic is real. Thickness and survival trends may provide insights but previous studies have been 
limited due to missing data on thickness. We conducted an analysis of invasive melanomas in the 
SEER-9 registries from 1989 to 2009 with a validated multiple imputation method for missing thick-
ness to characterize thickness and survival trends. 98,498 cases were identified of which 13% had 
missing data on thickness. Incidence per 100,000 person-years increased (14 to 22, P<0.001); fatal 
incidence remained stable (2.3 to 2.1, P=0.20); and 5-year relative survival increased (88 to 91%, 
P<0.001). Median thickness decreased (0.73 to 0.58 mm). Geometric mean thickness decreased 
(0.77 to 0.65 mm) with a 4.6% (95% confidence interval [CI]: 4.2, 5.0%) drop every three years after 
controlling for sociodemographic, tumor, staging and surgery factors. Thickness decreased among 
thin tumors (0.01-1.00 and 1.01-2.00 mm), all age and gender groups, whites, non-Hispanics, all 
body sites, and most histologic subtypes. Thickness increased among thick tumors (2.01-4.00 and > 
4.00 mm) and nodular melanoma. No change was observed among minorities and acral lentiginous 
subtypes. Melanoma-specific survival improved (hazard ratio [HR] 0.89, 95% CI: 0.88, 0.91) every 
three years after controlling for sociodemographic, tumor, staging and surgery factors. Improvement 
in survival occurred across all thickness groups, all age and gender groups, whites, most body sites 
and most histologic subtypes. Among minorities, and nodular and acral lentiginous subtypes there 
was no significant change. Increasing incidence across all thickness groups coupled with thin 
lesions getting thinner and thick lesions getting thicker suggests that the melanoma epidemic is at 
least partially real. Survival appears to be improving independent of thickness. Finally, disparities 
in thickness and survival are growing among minorities and nodular and acral lentiginous subtypes.   
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No treatment disparity in underinsured patients undergoing Mohs micrographic surgery for 
non-melanoma skin cancer at a single center
JL Walker, KC Lee and A Cruz Dermatology, Brown University, Providence, RI
This study assessed patient, tumor and treatment characteristics of an underinsured population 
referred to Mohs micrographic surgery (MMS) for non-melanoma skin cancer (NMSC) at a single 
university-affiliated academic Mohs center. A retrospective chart review was conducted of all MMS 
records between Jan 2011-Dec 2012. Controls were chosen as all insured patients who underwent 
MMS on the same day as any underinsured patient. Underinsured patients were categorized based 
on having no insurance, limited income-based insurance provided by the hospital or Medicaid. 
Analyses were conducted with χ2 and t-tests. Thirty underinsured patients with 62 lesions and 159 
insured patients with 385 lesions were included. The number of patients presenting with multiple 
lesions or recurrent tumor did not differ between the groups. The underinsured patients were more 
likely to be female (43% male (13/30) versus 65% male (103/159) P<0.01). There were significantly 
more squamous cell carcinoma in situ (SCCis) tumors treated in the insured population compared 
with the underinsured (36/385 vs 0/62; p<0.01). The underinsured were treated for more basal cell 
carcinomas (50/62 vs 228/385, p<0.01). The initial defect size, final defect size and number of 
Mohs tissue layers required for tumor extirpation were commensurate between groups. Repair types 
and referral to plastic surgery among the underinsured and insured did not differ. The underinsured 
population was less likely to be referred to MMS for SCCis, which may indicate more advanced 
tumors at time of presentation or use of different treatment modalities in this group. Otherwise, there 
was no indication of more aggressive or advanced NMSCs in the underinsured group suggesting 
comparable care of these patients. Repair types were no different based on insurance coverage 
indicating equal treatment within our Mohs surgery center. Higher referral rates to MMS for female 
underinsured patients may indicate greater cosmetic consciousness in this subgroup.    
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An analysis of personality styles and coping behaviors in chronic pruritus
S Booker,1 SP Kini,1 K Chen1 and SC Chen1,2 1 Dermatology, Emory University, Atlanta, GA 
and 2 Dermatology, Atlanta Veterans Affairs Medical Center (VAMC), Atlanta, GA
There is increasing interest in how the five main personality factors—neuroticism, agreeableness, 
conscientiousness, openness and extraversion—mediate coping behaviors in chronic illness. We 
seek to explore how the 10 personality ‘styles’, conceptualized by the intersection of each person-
ality factor (e.g. neuroticism vs. conscientiousness yields style of impulse control) mediate greater 
reported quality of life impact in chronic pruritus. Adult (≥18 years) subjects with chronic pruritus > 
6 weeks were recruited through the National Eczema Association or from a stratified random sample 
from the US Veterans National Patient Care Database. Subjects completed validated questionnaires 
to assess characteristics and impact of their pruritus (ItchyQoL) and personality traits (NEO-Five 
Factor Inventory). Multivariate regression analysis was performed to determine which personality 
styles were associated with greater total mean ItchyQoL score (more impact) as well as symptom 
(sx), emotion (em), and function (fx) subscale scores at the 0.05 significance level. The 483 sub-
jects in the final dataset were mostly (76%) male and had a mean itch duration of 23 weeks. The 
‘Lethargic’ personality style (low extraversion, low conscientiousness) was associated with greater 
total mean ItchyQoL score, (11.65 (p=0.04)) and trended to significance for fx subscale scores 
(3.71, p=0.07). Similarly those personality styles with high neuroticism, “Overcontrolled” (high 
neuroticism and high conscientiousness; 2.76, p=0.01) and “Undercontrolled” (high neuroticism, 
low conscientiousness; 2.34, p=0.03) were associated with greater sx subscale scores. Interestingly, 
no personality styles were associated with greater em subscale scores. These data suggest that there 
are distinct personality styles that may be implicated in how patients perceive, report, and cope with 
chronic pruritus which if addressed, may have the potential to significantly impact burden of disease.   
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Teledermatology programs in the veterans health administration
S Landow,1,3 DH Oh2,4 and MA Weinstock1,3 1 Dermatology, Brown University, Providence, 
RI, 2 Dermatology, UCSF, San Francisco, CA, 3 Dermatoepidemiology Unit, Providence VA 
Med. Ctr., Providence, RI and 4 Dermatology, San Francisco VA Med. Ctr., San Francisco, CA
The Veterans Health Administration (VHA) is likely the largest teledermatology provider in the US. 
We describe the teledermatology activity in the VHA using routinely collected administrative data. 
In fiscal year 2013, the VHA recorded 858,028 telehealth encounters, of which 6%, or 53,192, were 
teledermatology. This represents 25% of all teledermatology visits (n=213,772) recorded by the VHA 
since 2002, indicative of the rapid growth of the program. The VHA is divided into 22 geographical 
regions called Veterans Integrated Services Networks (VISNs), 20 of which used teledermatology in 
FY 2013. Two modes of teledermatology were used: Clinical Video Telehealth (CVT, or live video 
conferencing), in 7 VISNs, and Store and Forward Telehealth (SFT), in 20 VISNs. 96% of teleder-
matology enounters (50,863) in fiscal year 2013 were SFT; for the time period 2002-2013, 74% of 
teledermatology encounters (158,805) were SFT. Fiscal years 2012 to 2013 also showed decreased 
use of CVT and increased use of SFT. The Northwest VISN, serving Idaho, Oregon, Washington and 
Alaska, and Sunshine VISN, serving Florida, Puerto Rico, and the Virgin Islands, reported the highest 
number of encounters in the nation, each with 15% of the total. Nationally, 66% of the 2013 SFT 
encounters were performed within 7 days of referral; 80% were performed within 30 days. 55% of 
encounters were for patients living in urban areas (as defined by the U.S. Census), versus 42% in 
rural and 2% in highly rural (defined as <7 civilians per square mile) – the latter used only SFT. This 
report is limited by potential coding and data entry errors of these administrative data; these errors 
may lead to underestimation of encounters as well as overestimation of time to consult completion. 
VHA is a leader in the United States in using teledermatology to increase access to dermatology 
services for patients. It is transforming the mode of delivery of dermatology services to veterans as 
its use of teledermatology grows.    
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Treatment recommendations for melanocytic lesions vary among pathologists
KC Lee,1 MA Weinstock,1 P Frederick,2 M Piepkorn,2 A Zhao,2 JP Lott3 and J Elmore2 1 VA 
Med Ctr and Brown U, Providence, RI, 2 U of Washington, Seattle, WA and 3 Yale U, New 
Haven, CT
Therapeutic guidance by pathologists may influence the care of patients with melanocytic lesions. 
We examined the relationship between pathologist-level characteristics and treatment recommen-
dations for melanocytic lesions. We surveyed US pathologists to obtain individual professional and 
demographic information. Each was asked to provide treatment recommendations for the following: 
dysplastic nevi (mild, moderate, and severe), Spitz nevi (typical and atypical), melanocytic tumors 
of uncertain malignant potential (MELTUMP), melanoma in situ (MIS), and invasive malignant 
melanoma (MM). We assessed associations between pathologist characteristics and treatment 
recommendations with appropriate statistical testing. Sixty-eight surveys have been completed. 
Pathologists with dermatopathology training (p<0.001) and dermatopathology board certification 
(p<0.001) were more likely to recommend no treatment for mildly dysplastic nevi. Full-time aca-
demic appointment (p<0.01) and high monthly caseload of melanocytic lesions (p<0.02) were 
associated with aggressive therapeutic recommendations for moderately dysplastic nevi. For typical 
Spitz nevi, those requesting ≤2 second opinions/month were more likely to favor narrower re-ex-
cision margins (p=0.04). For atypical Spitz nevi, women (p=0.02) and high monthly caseload of 
melanocytic lesions (p=0.04) were associated with favoring aggressive treatment. The latter was also 
significantly associated with aggressive therapy for MELTUMP (p=.03). Twenty-seven pathologists 
made recommendations that differ from national guidelines for MIS, while 6 pathologists made 
recommendations that differed from national guidelines for MM. Those 60 years and older were 
more likely to make correct treatment recommendations for MM (RR 1.5), although this did not 
reach statistical significance. Treatment recommendations by pathologists exhibit large variation 
across pathologist-level factors. Efforts to reduce this variability should be a priority for quality 
improvement initiatives in dermatology.    
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Subjective component of SCORAD provides unique information when assessing atopic 
dermatitis
R Nakrani, M Glatz, C Booher, SM Steinberg and HH Kong NCI, NIH, Bethesda, MD
SCORing Atopic Dermatitis index (SCORAD) is a frequently used, validated tool for measuring AD 
severity. Total SCORAD consists of objective SCORAD (OS, extent and severity of AD) and subjec-
tive SCORAD (SS, pruritus and sleep loss). Use of OS alone is recommended because SS is affected 
by social and cultural factors that can unpredictably influence total SCORAD. However, pruritus 
and sleep loss are important components of AD with a significant impact on quality of life. There-
fore, we hypothesized that including SS in analysis of our AD patients might contribute clinically 
relevant information and/or correlate with cutaneous Staphylococcus aureus which is frequently 
associated with AD flares. OS and SS were determined for 15 children with moderate-to-severe 
AD at baseline (B), flare (F), and post-flare (PF) visits. In 12 children, skin microbial communities 
at sites of AD predilection (antecubital and popliteal fossae) were analyzed by 16S ribosomal RNA 
bacterial gene sequencing. OS and SS did not strongly correlate with each other at B (r=0.11, p=0.7), 
F (r=0.26, p=0.36), or PF (r=0.48, p=0.13) visits. Proportion of S. aureus at sites of AD predilection 
strongly correlated with OS (r=0.71, p<0.0001) and total SCORAD (r=0.70, p<0.0001) but weakly 
correlated with SS (r=0.47, p=0.004). The two components of SS were both similarly (and weakly) 
correlated with proportion of S.aureus (pruritus: r=0.41, p=0.01; sleep loss: r=0.39, p=0.02). In 
conjunction with prior studies, our findings suggest that because they are weakly correlated, both 
SS and OS may provide distinct information on AD severity. Thus, standardized reporting of both 
components in AD studies may be informative. Furthermore, both pruritus and sleep loss in AD 
fluctuate independently from cutaneous S.aureus colonization in our cohort. Further studies are 
needed to determine how objective and subjective assessments of AD differentially correlate with 
microbial community structure.    
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Variations in incidence and survival of cutaneous melanoma by race in the united states
SM Dawes,1 H Gittleman,2 JS Barnholtz-Sloan2 and J Bordeaux1 1 Dermatology, Case 
Western Reserve University, Cleveland, OH and 2 Case Comprehensive Cancer Center, Case 
Western Reserve University, Cleveland, OH
Cutaneous melanoma is an aggressive form of skin cancer with high incidence rates in the US. It is 
a commonly diagnosed cancer among men and women. Melanoma incidence varies by race, with 
Whites predominating, followed by Hispanics, American Indians/Alaskan Natives/Asian/Pacific 
Islanders, and Blacks, respectively. To determine whether disparities existed, survival was stratified 
by race. Data was acquired from the National Cancer Institute Surveillance, Epidemiology, and End 
Results (SEER) Program. Data from 1973-2009 was compiled and the Kaplan-Meier method was used 
to calculate survival for cohorts by race, and race stratified by stage at presentation. White patients 
presented with the highest percentage (75.97%) of Stage I diagnosis (95% CI: 75.62,76.31). Black 
patients presented with the highest percentages for stages II-IV: 22.82 (95% CI: 18.42,27.91), 13.42 
(95% CI: 10.01,17.76), 11.07 (95% CI: 7.99,15.14), respectively. Ten year survival was greatest 
for Whites, followed by Hispanic, Blacks, and American Indians/Alaskan Natives/Asian/Pacific 
Islanders (p= 1.12e-05). Despite higher incidence, overall survival is greater in whites compared 
to Nonwhites. Black patients had significant increases in mortality for Stage I: Hazard Ratio (HR) 
3.037 (95% CI: 2.335, 3.951) and stage III: HR 1.864 (95% CI: 1.211, 2.87), compared to Whites 
(reference). Source of payment may have significance in the contribution to this disparity. This 
epidemiological study has public health implications. Despite low incidences, minorities have 
significantly increased mortality compared to Whites; this data is evidentiary of sociocultural health 
disparities consistent with other illnesses. Linking results of the study to health outcomes based on 
racial demographics shows that screening and treatment of minorities can be improved. Dissem-
ination of the data presented can change standards of care, improve population health, and open 
investigation into other determinants that may affect minority populations.    
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Rosacea has an increased association with skin cancer
P Shoureshi,1 DY Rowland2 and J Bordeaux1,3 1 Dermatology, University Hospitals Case 
Medical Center, Cleveland, OH, 2 Epidemiology and Biostatistics, Case Western Reserve 
University School of Medicine, Cleveland, OH and 3 Dermatology, Case Western Reserve 
University School of Medicine, Cleveland, OH
The relationship between rosacea and skin cancer is unclear with no reported studies since the 
classification of rosacea in 2002. Questionnaires were distributed to a voluntary cohort of twins 
at the 2012 and 2013 annual Twinsdays Festival. The survey included each participant’s age, 
gender, ethnicity, Fitzpatrick skin type, sun exposure history by age and geographic location, 
and skin cancer history. Adults were evaluated for rosacea by a dermatologist. After excluding 
individuals under the age of 50, participants were divided into a rosacea group and a rosacea-free 
control group. An increased number of skin cancers were identified among the rosacea group 
(19.15%) as compared to the control group (2.22%). Multivariate analysis demonstrated an odds 
ratio of 12 (p = 0.02) for skin cancer development among rosacea cases as compared to controls. 
Clinical practitioners should consider skin cancer screening among their rosacea patients as it may 
represent a potential risk factor.    
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Hidradenitis suppurativa is a disease of significant co-morbidity burden: Results from a 
case-control analysis of a large patient database
J Shlyankevich,1 AJ Chen,2 GE Kim3 and AB Kimball1,3 1 Dermatology, Massachusetts 
General Hospital, Boston, MA, 2 Alpert Medical School, Brown University, Providence, RI 
and 3 Harvard Medical School, Boston, MA
Previous epidemiologic studies describing hidradenitis suppurativa (HS) have been limited by small 
sample sizes. The purpose of this retrospective, case-control study was to report the co-morbidities 
of HS in a large patient care database. Within the Partners Healthcare Research Patient Database 
Registry (RPDR), all patients who received at least two International Classification of Disease, 
Ninth Revision codes consistent with HS (705.83) were identified and then manually screened 
for validation of the HS diagnosis by chart review. A control population was matched for age, 
gender, and race. The RPDR query returned 1,168 patients with at least two HS codes, and of 
these, 1,046 (90%) were confirmed as having HS. HS cases had a mean age of 44 years, and 72% 
were female. 67% were white, 14% were black, and 13% were Hispanic. Chi-square comparisons 
between the case and control groups demonstrated that patients with HS were significantly more 
likely than the controls to have all of an a priori selected set of co-morbidities including current 
or former smoker (p<.01), obesity (p<.01), dyslipidemia (p<.01), hypertension (p<.01), diabetes 
mellitus ( p<.01), thyroid disorder (p<.01), mental disorder (p<.01), arthropathies (p<.01), polycystic 
ovarian syndrome (p<.01), alcohol dependence (p<.01), and drug dependence (p<.01). These data 
demonstrate a substantially higher co-morbidity burden associated with HS compared to controls. 
We recommend a multidisciplinary approach to treating these patients, including close follow-up 
with a dermatologist and evaluation for metabolic syndrome, cardiovascular risk factors, and psy-
chological co-morbidities.    
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Smoking increases the of CLASI in subjects with moderate to severe systemic lupus 
Erythematosus
V Werth,1,2 MA Khamashta,3 GG Illei,4 S Yoo,4 L Wang4 and W Greth4 1 Dermatology, 
Philadelphia PVAMC, Philadelphia, PA, 2 Dermatology, University of Pennsylvania, 
Philadelphia, PA, 3 Lupus Research Unit, London School of Medicine, London, United 
Kingdom and 4 Medimmune, Gaithersberg, MD
The goal of the study was to evaluate the influence of smoking on the severity of cutaneous manifes-
tations of adults with moderate to severe SLE. In this ongoing international multi-center double-blind 
randomized placebo-controlled trial in adult SLE (94.7% female, median disease duration 6.3 
years, 59% white, 37% Hispanic, median age of 40 years old, mean SLEDAI 2K 11.3, with 84.7%, 
72.4%, 49.9% receiving corticosteroids, antimalarials, or immunosuppressants respectively) subjects 
(n=431) were assessed for mucocutaneous disease activity (CLASI (N=426), SLEDAI2K, BILAG) at 
baseline based on smoking history at screening. There were N=365 Never or Past Smokers and N=61 
Current smokers. Based on SLEDAI 2K scoring at baseline 79%, 67% and 45% had an inflammatory 
rash, alopecia or mucosal ulcers with no significant differences between smokers and non-smokers. 
Current smokers had significantly higher CLASI scores and were more likely to have moderate or 
severe rash (CLASI ≥ 10). This observation was consistent across geography, races ethnicities, and 
SLE medications at baseline There was no relationship between smoking and cutaneous damage. 
We show that smoking can increase CLASI scores in subjects with SLE compared to non-smokers. 
The CLASI seems more sensitive to detect these differences of inflammatory skin involvement in 
SLE subjects with moderate to severe SLE than the SLEDAI 2K mucocutaneous descriptors (alopecia, 
rash, mucous ulcers). The relationship between smoking and higher CLASI scores compared to 
non-smokers is consistent across geographies, races, ethnicities and SLE medications at baseline. 
These results show that current smokers with lupus have worse skin involvement than non-smokers. 
Smoking cessation should be emphasized in the management of SLE with cutaneous involvement.   
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Severe atopic dermatitis in an African-American pediatric cohort is associated with a filaggrin 
low intragenic copy number variant
A Quiggle, Z Goodwin, TC Pansuriya, M Kumar-Gupta, E Beck, E Gurnee, H Ciliberto, 
KJ Gulewicz, SJ Bayliss and C de Guzman Strong Washington University School of Medicine, 
St. Louis, MO
The prevalence of atopic dermatitis (AD) is higher in African-American (AA) children with a 
strong family history of atopic dermatitis. However, the genetics underlying AD in AA children 
are unknown. We examined the AD clinical phenotype and the role of filaggrin (FLG) genetic 
variants in a pediatric AA cohort by measuring disease severity (SCORAD) and genotyping methods, 
respectively. Pediatric patients (ages 1-18, n=38) that self-report as African-American were recruited 
to the study by meeting the UK Working Party’s diagnostic criteria for AD and exhibited moderate 
to severe AD (SCORAD>25). Our AA pediatric cohort (mean age=6.4, range 1-15) is character-
ized by severe AD (mean SCORAD=57.6, range 28.0-90.5), intense pruritis (mean=7.8, 0-10), 
and severe disruption of Quality-of-Life (mean=7.8, scale 1-10). As well, 53% reported suffering 
from food allergies (26%, peanut; 26%, fish/shellfish) and 81% (>4 years) were symptomatic for 
asthma. Lichenification (mean=2.18, scale 0-3) contributed the most to the representative flare thus 
supporting the chronicity of the disease in this cohort. Moreover, dryness in the nonlesional skin 
ranked the highest in mean severity (mean=2.21, scale 0-3) among all reportable quantitative and 
objective skin measures. Fewer FLG monomer repeats in exon 3 (genotyped as 10, 11, and 12 repeat 
alleles or copy number variants [CNV]) have been previously associated with higher AD risk. From 
genotyping assays, we determined that 47% of the AA cohort is homozygous for 10 FLG monomer 
repeats (10/10), and that the 10/10 genotype is associated with the development of severe AD (OR 
= 1.64; 95%CI, 0.44-6.11). Thus, our study furthers our understanding of the distinguishing clinical 
features of severe AD in an AA pediatric cohort that until now has been largely underexplored and 
identifies a low intragenic FLG copy number variant associated with AD severity.    
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Association of melanoma incidence with biopsy and excision rates, 2008-2010
MA Weinstock,1,2 H Pomerantz,1,2 T Onega,3 Q Wang,3 A Tosteson,3 J Lott,5 L Titus,3 
L Pearson3 and J Elmore4 1 VA Med Ctr, Providence, RI, 2 Brown Univ, Providence, RI, 3 
Dartmouth College, Hanover, NH, 4 Univ of Washington, Seattle, WA and 5 Yale Univ, 
New Haven, CT
Prior research has demonstrated a parallel pattern of increasing melanoma incidence and skin 
biopsy rates; it is still debatable if the latter is responsible for the former. We sought to further eval-
uate the relationship between melanoma incidence and skin biopsies. We used the Surveillance, 
Epidemiology, and End Results Program (SEER) – Medicare data in years 2008-2010 to examine 
age-adjusted melanoma incidence and skin biopsy and excision rates across calendar time, age, sex, 
and SEER Registry. Age-adjusted incidence of invasive melanoma in years 2008-2010 was 21.3 per 
100,000, and in situ melanoma was 15.5. Over this 3-year period, incidence of invasive melanoma 
remained unchanged, but in situ melanoma increased by about 10%. Age-adjusted rates of both 
skin biopsy and excision also increased by about 10%. Incidence of invasive melanoma in years 
2008-2010 was lowest in ages 65-74 and highest in ages 85+ for both men and women over ages 
65. In situ melanoma incidence increased with increasing age for men, but for women it was higher 
in ages 75-84 than ages 65-74 and 85+. Both biopsy and excision rates were also higher in ages 
75-84 than the other age groups. Men had 65% and 67% higher incidence of invasive and in situ 
melanoma, and a 60% higher rate of biopsies and excisions than women. For the 10 states covered 
by SEER registries, the correlations of invasive melanoma incidence to biopsy and excision rates 
were .36 and .24, respectively (p>.1 for each), but the correlations of in situ melanoma incidence to 
biopsy and excision rates were .61 and .52 (p=.03 and .06, respectively.) Skin biopsy and excision 
rates were closely parallel to in situ melanoma incidence, but they were also parallel to invasive 
melanoma incidence to a lesser degree. These ecological correlations offer limited insights into 
cause and effect, but suggest that the increasing rate of in situ melanoma may reflect increased 
procedural diagnostic utilization.    
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Assessment of preferences and need for a psoriasis patient decision aid
FS Ortenzio,1 R Kost,2 D Brassil,3 J Kim,1 AD Robertson,4 JG Krueger,1 JN Tobin5 and 
MA Lowes1 1 The Laboratory for Investigative Dermatology, The Rockefeller University, 
New York, NY, 2 Hospital Clinical Research Office, The Rockefeller University, New York, 
NY, 3 Clinical Research Facilitation, The Rockefeller University, New York, NY, 4 National 
Psoriasis Foundation, Portland, OR and 5 Clinical Directors Network, New York, NY
The recent expansion of treatment options for the common skin disease, psoriasis, will likely lead to 
greater collaboration between patients and healthcare practitioners in the decision-making process. 
‘Shared Decision-Making’ has been shown to increase satisfaction with care, and may be enhanced 
by using tools such as Patient Decision Aids (PDAs) that can increase health literacy levels and 
personalize the treatment decision-making process. While a paper-based Psoriasis PDA currently 
exists (Tan and Wolfe, Arch Dermatol, 2012), our overall goal is to create the first web-based, inter-
active PDA for psoriasis patients, using a Patient-Centered Outcomes Research (PCOR) approach. 
To assess the perceived need of a PDA by psoriasis patients, 5 focus groups were conducted under 
an IRB-approved protocol, engaging a total of 25 individuals with mild to severe psoriasis. Partic-
ipants ranged in age from 21-73 years (mean of 52 years) with duration of disease ranging from 
3-49 years. Focus group participants strongly favored the creation of an informative and clear PDA 
for psoriasis. They expressed the need for a comprehensive list of treatment choices, with treatment 
effectiveness, safety and side-effects data, as well as disease and drug interactions. Patients indicated 
they would also value adding theses utilities to the PDA: ability to sort by preference for method 
of administration and information on available clinical trials and promising new agents. Patients 
also value data on alternative health approaches, insurance requirements, and provider areas of 
expertise. Next steps are to develop an evidence-based Psoriasis PDA prototype for testing, with 
input from all interested stakeholders.    
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 Methylisothiazolinone (MI), a new and frequent contact allergen: Relevance and outcomes 
from clinical practice 
SH Yu,1 JS Taylor,2 D Murray2 and A Sood2 1 Dermatology, Case Western Reserve University, 
Cleveland, OH and 2 Dermatology, Cleveland Clinic, Cleveland, OH
The purpose of this study was to determine the prevalence, co-reaction patterns, and outcomes of 
patients patch tested with methylisothiazolinone (MI) and methylchoroisothizolinone/ methyliso-
thiazolinone (MCI/MI) as part of our standard patch test series. A retrospective chart review was 
conducted of patients patch tested with MI and MCI/MI in 2012 and 2013 according to methods of 
the North American Contact Dermatitis Group. Demographic data, exposures, and outcomes was 
recorded in patients with positive reactions. During this time, 382 patients were patch tested. Contact 
allergy to MI and/or MCI/MI occurred in 34 (8.9%), with 17 reactions to MI only, 1 reaction to MCI/
MI only, and 16 reactions to both. Most were female (73%); average age was 47 years. Average 
duration of dermatitis before patch testing was 30 months and most patients (60%) had a history 
of atopy. Most commonly affected sites were hands (n=13), face (n=11), and generalized (n=10). 
Contact allergy was occupationally related in four cases; three were hairdressers using shampoos 
containing MI and a fourth was a daycare worker utilizing MI-containing wet wipes. Relevance of 
exposures was identified and rated definite (n=2), probable (n=12), possible (n=11), or past (n=2). 
Cosmetics, soaps and cleansers (including personal wet wipes), and hair care products accounted for 
all identified sources. Concomitant allergy occurred to other preservatives: methyldibromo glutaro-
nitrile/phenoxyethanol (n=6), iodopropynyl butylcarbamate (n=5), formaldehyde (n=5), bronopol 
(n=4). Outcomes were available for 12 patients; most improved with allergen avoidance: cleared 
(n=4), mostly cleared (n=5), and partially cleared (n=1). The high prevalence of contact allergy to 
MI supports its addition to standard patch test series to identify cases missed by testing with only 
MCI/MI. Intervention is needed to reduce the number of products containing these preservatives.   
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Presence of dermal atypia in malignant melanoma in situ: effect on management and outcome
LX Tong and JY Lin Dermatology, Brigham and Women’s Hospital, Boston, MA
Melanoma is one of the deadliest forms of skin cancer, having a high metastatic potential and afflict-
ing all age groups. The onus to detect melanoma at its earliest, curable stage drives clinical practice. 
Malignant melanoma in-situ (MMIS) is thought to be a precursor lesion to malignant melanoma, 
and incidence has been increasing particularly in the last decade. MMIS is poorly characterized 
with various treatment approaches, and many physicians are unsure of the progression of MMIS 
to metastatic disease. The importance of margin individual melanocytes following excision is also 
unclear. The purpose of this study was to characterize the natural history of MMIS and to investigate 
the influence of dermatopathology comments regarding the presence of dermal melanocytes on 
management. A retrospective review of patients with a new pathologically proven diagnosis of 
MMIS at the Brigham and Women’s Hospital was performed. All qualifying subjects from 2003-
2004 were identified and entered into a comprehensive database. Patients without recent follow-up 
were excluded. Types of excision, excision margins, and disease outcomes were compared between 
patients with and without dermal atypia on pathology. Our population had a 10-year survival rate 
of 98.8%, with deaths resulting from metastatic melanoma. Most patients underwent a wide local 
excision (WLE) with margins of 0.5 cm (81.3%), and an overall recurrence rate of 2.07% was 
observed. Patients that demonstrated dermal atypia on pathology had an increased rate of WLEs 
with wider excision margins. Interestingly, a high percentage (28.6%) of multiple melanomas was 
noted. MMIS has an excellent prognosis if treated early and appropriately. Our findings may serve 
to reduce the morbidity associated with WLEs and to clarify the prognosis and etiology of MMIS.   
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Gallstones and risk of incident psoriasis and psoriatic arthritis in U.S. women
LX Tong,1,3 S Wu,1 EL Giovannucci3,2 and A Qureshi1,2 1 Dermatology, Brigham and 
Women’s Hospital, Boston, MA, 2 Channing Laboratory, Department of Medicine, Brigham 
and Women’s Hospital, Boston, MA and 3 Harvard School of Public Health, Boston, MA
Metabolic syndrome and obesity are known to be strongly associated with both psoriasis and gall-
stones, implying possible common causal factors. However, the association between psoriasis and 
gallstones has not yet been studied. Our study investigated the association between psoriasis and 
gallstones in the Nurses’ Health Study II (1991-2005). A total of 95,540 participants were identified. 
In this population, 813 individuals had a diagnosis of psoriasis and 1,663 patients had gallstones 
confirmed by a history of cholecystectomy at baseline; an additional 622 women developed psoriasis 
during the follow-up, and 6,907 women developed gallstones during the follow-up. A baseline 
history of gallstones was found to be associated with increased risk of psoriasis [hazard ratio (HR) 
= 2.20; 95% CI: 1.46, 3.31] and increased risk of psoriasis with concomitant PsA as well (HR = 
4.79; 95% CI: 2.70, 8.50). After adjusting for BMI and other known risk factors for psoriasis and 
gallstones, a history of psoriasis with concomitant PsA continued to demonstrate an increased risk 
of gallstones (HR = 2.56, 95% CI: 1.41, 4.65), as did a history of psoriasis alone (HR = 1.55, 95% 
CI: 1.02, 2.37). In this study, we found that a history of gallstones is associated with an increased 
risk of psoriasis and PsA.    
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The epidemiology of Lyme disease in the state of Massachusetts, 2001-2011
EF Firoz and A Qureshi Dermatology, Brigham and Women’s Hospital, Boston, MA
Lyme disease, a notifiable, multisystem illness caused by the bacterium, Borrelia burgdorferi, spreads 
through the bite of infected ticks and is a growing public health concern. The Massachusetts 
Department of Public Health receives Lyme disease reports from healthcare providers and from 
clinical laboratories. In Massachusetts between 2001 and 2011, a total of 28,727 cases of Lyme 
disease were reported; the annual count increased 134%, from 1,236 cases in 2001 to 2,887 cases 
in 2011. During this 10-year period, 68% of cases manifested erythema migrans, 32% arthritis, 9% 
Bell’s palsy, 3% radiculoneuropathy, 3% lymphocytic meningitis, and 1% second- or third-degree 
atrioventricular block. Information regarding race was available for 18,912 (66%) reported cases. Of 
these, 18,311 (96.8%) patients were identified as white, 249 (1.3%) as other, 224 (1.2 %) as Asian, 
and 128 (0.7%) as black. Lyme disease is highly concentrated in the northeast and north-central 
states, with Massachusetts having one of the highest prevalence rates. During 2001-2011, the 
number of reported cases more than doubled. These results highlight the continued emergence of 
Lyme disease and the need for tick avoidance and early treatment interventions.    
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 Eczematous response to squaric acid sensitization not required for scalp treatment initiation 
in alopecia areata 
P Vedak1 and D Kroshinsky1,2 1 Massachusetts General Hospital, Boston, MA and 2 Harvard 
Medical School, Boston, MA
There are conflicting reports regarding the necessity of an initial eczematous reaction at the site of 
squaric acid dibutylester (SADBE) sensitization for alopecia areata with concentrated SADBE prior 
to the initiation of continued scalp treatment with more dilute solutions. While some authors pur-
port that the absence of an eczematous reaction does not imply that sensitization has failed, others 
specify the need for repeated sensitization attempts until such a reaction is noted. A retrospective 
chart review was conducted to survey the various SADBE treatment regimens used in the treatment 
of alopecia areata at our institution over a period of sixteen years, and to evaluate their efficacy at 
sensitization as measured by the ability to elicit hair regrowth. 339 patients were treated for alopecia 
areata, of which 13 (9 women and 4 men, mean age 13 years, range 6 to 32 years) received treatment 
with SADBE. 3/13 patients demonstrated an eczematous reaction at the sensitization site after the 
first sensitization attempt and hair regrowth with continued treatment. 5/13 patients underwent 
multiple sensitization attempts (median 2, range 2-6) prior to the development of an eczematous 
reaction at the sensitization site. Four out of these 5 sensitized patients chose to pursue continued 
treatment and all demonstrated hair regrowth. Of the 5/13 patients that either forwent sensitization 
or failed to demonstrate an eczematous reaction at the sensitization site, the three that nonetheless 
pursued continued treatment all demonstrated hair regrowth. Thus, SADBE sensitization regimens 
and reactions demonstrate great variability and the absence of an initial eczematous reaction to 
sensitization does not predict a failed response with continued SADBE treatment. Consequently, 
a larger group of patients may be candidates for SADBE therapy than certain treatment regimens 
imply and an initial concentrated sensitization application may be unnecessary in some cases. 
Further studies are required to identify the most efficacious and cost-effective treatment regimen.   
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Annual percentage change of incidence rate of Merkel cell carcinoma has declined in the 
United States
X Zhou,1 Y Chen,1 JS Barnholtz-Sloan1 and J Bordeaux1,2 1 Case Western Reserve University, 
Cleveland, OH and 2 University Hospitals, Cleveland, OH
Merkel cell carcinoma (MCC) is a rare skin cancer that has shown increasing annual incidence since 
its initial description. Given the high mortality rate of this disease relative to other skin cancers, it is 
important to continue monitoring the incidence and prognosis of MCC. The study was conducted 
using the SEER 18 database to analyze annual incidence of MCC and age-adjusted 5-year survival 
rate. A total of 4803 cases were identified during this time interval. Of these cases, there were 
4732 unique patients. There were 2927 males (62%) and 1805 females (38%). The analyses were 
performed based on sex, age, and stage of disease. Analysis showed an increasing trend in the 
annual incidence of MCC from 2000 to 2010, with an annual percentage change (APC) of 2.4% 
(CI = 1.3, 3.6). This annual percentage change is significantly lower than that found in a previous 
study on MCC incidence changes from 1986 to 2001 (EAPC = 8.08; CI = 6.29, 9.90). The APC in 
the female population (APC = 3.3, CI = 1.0, 5.6) is much higher than in the male population (APC 
= 1.8; CI = 0.2, 3.4) although overall annual incidence of MCC is higher in the male population. In 
addition, multivariate Cox proportional hazards models showed that 5-year survival rate is greater 
in female than in male patients regardless of stage of disease (Local: 55.4% vs. 48.8%, Regional: 
51.1% vs. 41.5%, Distant: 26.7% vs. 14.1%). The study also found a significant difference in the 
distribution of staging (local, regional, distant) between males and females patients less than 55 years 
old. In this age group, women were more likely to have localized disease compared to men, who 
are more likely to have regional disease (p = 0.019). In conclusion, this study supports a decline in 
the rate of increase in incidence of MCC. Additionally, the 5-year survival rate is higher in female 
patients in all stages of MCC.    
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Prevalence of psoriasis phenotypic subsets among U.S. men and women
JF Merola,1 T Li2 and AA Qureshi1,2 1 Dermatology, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, MA and 2 Medicine, Channing Division of Network Medicine, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Objective: Psoriasis is highly prevalent in the US and presents with several phenotypes, includ-
ing chronic plaque, nail, scalp, palmo-plantar and inverse (intertriginous) psoriasis. We present 
important prevalence data evaluating psoriasis phenotypic subsets based on three large cohorts: 
Health Professionals Follow-up Study (HPFS) and Nurses’ Health Study (NHS) and Nurses’ Health 
Study 2 (NHS2). Methods: Psoriasis diagnoses were self-reported among subjects using the Psoriasis 
Screening Tool. Psoriatic phenotypic subtypes: chronic plaque, scalp, inverse, palmoplantar, and 
nail psoriasis. The HPFS (1986-2010) includes 51,529 males ages 40-75. The NHS (1998-2010) 
includes 121,701 female nurses ages 30-55. NHS2 (1991-2005) includes 116,686 women between 
the ages of 25-42. Results: The total number of patients with psoriasis was n=1611 (NHS), n=1593 
(NHS2), and n=646 (HPFS). Plaque disease among NHS, NHS2 and HPFS was 56% (n=902), 60% 
(n=956) and 56% (n=362). Scalp disease prevalence was 52% (n=838), 55% (n=876) and 45% 
(n=291). Palmoplantar disease prevalence was 14% (n=226), 14% (n= 223) and 12% (n=78). Nail 
disease among the groups was 23% (n=371), 26% (n= 419) and 27% (n=174). Inverse disease was 
21% (n=338), 24% (n=382) and 30% (n=194). Concurrent non-plaque subsets of note included: 
nail+scalp NHS, NHS2 and HPFS were 14%, 14% and 17%; scalp+inverse: 14%, 17% and 16%; 
nail+scalp+inverse 6%, 8%, 8%. Conclusion: The prevalence of non-plaque phenotypes, occurring 
concurrently with or without plaque disease, is high and may approach the prevalence of plaque 
disease itself. These phenotypic subsets have been reported in other studies to significantly affect 
patient’s quality of life and, in some cases, are associated with increased risk of psoriatic arthritis. 
This data represents the largest report of psoriasis phenotypic subset prevalence data to date and is 
important for framing future studies.    
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Citrus consumption is associated with risk of malignant melanoma
S Wu,1 J Han,2,3,4 D Feskanich,2 MJ Stampfer,2,3,5 WC Willett2,3,5 and AA Qureshi1,2,6 1 
Dermatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 
2 Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 3 
Epidemiology, Harvard School of Public Health, Boston, MA, 4 Epidemiology, Fairbanks 
School of Public Health, Simon Cancer Center, Indiana University, Indianapolis, IN, 5 
Nutrition, Harvard School of Public Health, Boston, MA and 6 Dermatology, Alpert Medical 
School, Brown University, Providence, MA
Citrus products are dietary sources of psoralens, a group of chemicals that have photocarcino-
genic properties. We examined the association between citrus consumption and subsequent inci-
dent malignant melanoma among participants in the Nurses’ Health Study (1984-2010) and the 
Health Professionals Follow-up Study (1986-2010). Among 105,437 participants over 2 million 
person-years of follow-up, we documented 1857 incident melanomas. The pooled multivariate-ad-
justed hazard ratio for melanoma comparing the extreme total citrus consumption categories (1.5 
or more serving per day vs. less than twice per week) was 1.30 (95 confidence interval [CI], 1.08 
to 1.57) (P=0.003 for trend). Grapefruit and orange juice were two individual citrus products that 
showed significant associations with risk of melanoma. The pooled multivariate-adjusted hazard 
ratios for melanoma were 1.41 (95% CI, 1.09 to 1.82) comparing the extreme consumption cate-
gories of grapefruit (three times or more per week vs. never, P=0.004 for trend) and 1.26 (95% CI, 
1.02 to 1.56) comparing the extreme consumption categories of orange juice (once or more per 
day vs. never, P=0.001 for trend). Significant positive associations between citrus consumption and 
risk of melanoma were also observed for invasive melanoma and melanoma that occurred on the 
head, neck and extremities, and among participants who spent more time in direct sunlight since 
high school and resided in areas with higher solar ultraviolet radiation in the US. In conclusion, 
we found that consumption of grapefruit and orange juice was positively associated with risk of 
malignant melanoma among US women and men.    
342
Ranking the most disabling skin diseases in the United States of America in 2010
R Dellavalle,1,2,3 C Karimkhani4 and LN Boyers5 1 Dermatology, University of Colorado 
School of Medicine, Aurora, CO, 2 Epidemiology, Colorado School of Public Health, Aurora, 
CO, 3 Dermatology, Dept. of Veterans Affairs Medical Center, Denver, CO, 4 Columbia 
University College of Physicians and Surgeons, New York, NY and 5 Georgetown University 
School of Medicine, Washington, DC
The Global Burden of Disease (GBD) project (www.healthmetricsandevaluation.org) estimates the 
disability caused by skin diseases using the metric of disability-adjusted life years (DALYs). DALYs 
equal the sum of years lost to a disease (mortality) plus years lived with disability (morbidity). 
The GBD project systematically reviews the epidemiologic literature and uses IDC-9 and ICD-10 
definitions of disease. Using prevalence and disease severity adjustment measures the GBD project 
estimates relative disability measures for all diseases more precisely than ever before. According to 
this data in 2010 the top 13 most disabling skin diseases in the USA were: 1) dermatitis (390,233 
DALYs) 2) non-melanoma skin cancer (230,918 DALYs) 3) melanoma (220,168 DALYs) 4) acne 
vulgaris (203,374 DALYs) 5) pruritus (134,569 DALYs) 6) viral skin diseases (119,512 DALYs) 7) 
urticaria (112,689 DALYs) 8) bacterial skin diseases including cellulitis (91,382 DALYs) 9) decubitus 
ulcer (84,763 DALYs) 10) fungal skin diseases (70,655 DALYs) 11) psoriasis (64,342 DALYs) 12) 
alopecia areata (58,662 DALYs) and 13) scabies (24,109 DALYs). The 3 skin disease showing the 
greatest increase in DALYs since 1990 were: 1) non-melanoma skin cancer (118,768 more DALYs 
in 2010), 2) dermatitis (86,398 more DALYs in 2010) and 3) melanoma (41,159 more DALYs in 
2010). These skin disease disability rankings provide new transparent data to inform US dermatology 
research, public policy, and resource allocation.    
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Looking for a journal with the most social media impact: JID tops facebook while JAMA 
Dermatology tops twitter
C Karimkhani,1 R Gamble2 and R Dellavalle2,3,4 1 Columbia University College of Physicians 
and Surgeons, New York, NY, 2 University of Colorado School of Medicine, Aurora, CO, 
3 Colorado School of Public Health, Aurora, CO and 4 Dept. of Veterans Affairs Medical 
Center, Denver, CO
While academic authors routinely appraise journal impact factors when determining where to 
submit their manuscripts, they may now also consider journal social media impact. We examined 
dermatology journal presence on social media. We searched Facebook and Twitter for 100 peer-re-
viewed dermatology journals found in the journal database SCImago on 5/30/12. We also searched 
for three additional popular peer-reviewed dermatology journals (JAMA Dermatology, Journal of 
Clinical and Experimental Dermatology Research, Journal of Dermatology Nurses’ Association) and 
two trade publications (Dermatology Times, Practical Dermatology) not listed in SCIMago. Facebook 
“like” and twitter “follower” numbers were updated on 12/12/13 for the subset of the top ten most 
active dermatology journals and trade publications on social media. Five journals/trade publications 
were on the top ten for both Facebook likes and Twitter followers: Cutis, JAMA Dermatology, Journal 
of Clinical and Experimental Dermatology Research, Journal of Dermatology Nurses’ Association, 
and Practical Dermatology. Of peer-reviewed journals, the Journal of Investigative Dermatology 
(6736) and JAMA Dermatology (4693) had the greatest absolute numbers of Facebook “likes” and 
Twitter “followers.” Of note, with the inclusion of trade publications, Dermatology Times (7504) 
had the greatest absolute number of Twitter “followers” on 12/12/13. All top ten dermatology jour-
nals experienced a minimum 100% increase in Facebook “likes” or Twitter “followers” over the 
18 months studied. Our data suggest modest but increasing use of social media among readers of 
dermatology journals. The results of our study provide evidence that authors should also consider 
a journal’s social media impact when considering manuscript publication.    
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Representation of the most disabling skin diseases in the USA in The National Institute of 
Arthritis and Musculoskeletal and Skin Diseases grants 
C Karimkhani,1 LN Boyers,2 DJ Margolis3 and R Dellavalle4,5,6 1 Columbia University College 
of Physicians and Surgeons, New York, NY, 2 Georgetown University School of Medicine, 
Washington D.C., DC, 3 Perelman School of Medicine, University of Pennsylvania, 
Philadelphia, PA, 4 University of Colorado School of Medicine, Aurora, CO, 5 Colorado 
School of Public Health, Aurora, CO and 6 Dept. of Veterans Affairs Medical Center, 
Denver, CO
The Global Burden of Disease (GBD) 2010 project established dermatitis, non-melanoma skin 
cancer, and melanoma as the three most disabling skin conditions in the USA using the metric of 
disability-adjusted life years (DALY). We examined how well grant topics funded by The National 
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) reflect skin disease burden in 
the USA. Grants awarded by NIAMS in 2013 were categorized into skin disease categories measured 
by the GBD. Twenty percent of NIAMS grants covered dermatologic topics which received 19.6% 
of total funding. Dermatitis, the most disabling skin disease, was well represented (n=20). The 
next most disabling skin diseases, non-melanoma skin cancer and melanoma, had the highest (35) 
and third highest (16) grant representation, respectively. Eight-six grants covered topics in GBD’s 
“other skin and subcutaneous diseases” category and an additional 102 grants covered general 
skin research, skin research unspecified, conferences, training, and miscellaneous skin conditions. 
Twelve of the 15 of the most disabling GBD skin disease categories were represented in the NIAMS 
grant database. Many factors may guide dermatologic research prioritization, including whether 
disease disproportionately affects disadvantaged populations, availability and lack of cost-effective 
interventions, interest-group advocacy, and public interest. US GBD data should inform future 
NIAMS research funding prioritization.    
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Increased news coverage of the risks of indoor tanning after the California indoor tanning 
ban for minors
JE Mayer,1,4 AC Geller,1 SM Swetter2 and S Guild3 1 Harvard University School of Public 
Health, Boston, MA, 2 Stanford University, Palo Alto, CA, 3 AIM at Melanoma, Richmond, 
CA and 4 Columbia University College of Physicians and Surgeons, New York, NY
Indoor tanning devices are a known carcinogen. Several states have passed laws banning minors 
from using them, and many other states are now weighing the benefits and costs of similar bans. 
Therefore, the objective of this study was to determine whether initial passage of the California 
indoor tanning ban for minors was associated with longer-term media coverage of skin cancer 
prevention and the risks associated with tanning beds. Articles from 31 English-language California 
newspapers between June 2010-May 2011 (PRE) and June 2011-May 2012 (POST) were searched 
using terms related to skin protection. 90 articles with a major theme of skin protection were 
found for in-depth coding and analysis. The main outcome analysis compared PRE and POST 
number/percentage of skin protection articles – in total, that mention risks of indoor tanning, and 
that mention skin cancer prevention and sunscreen-specific recommendations. There were almost 
twice as many skin protection articles in the POST period as there were in the PRE period (57 vs 
33; P<.05). In addition, there were more than three times as many POST articles mentioning the 
risks of indoor tanning (33 vs 10; P<.001). A POST article was almost twice as likely to mention 
the risks (58% vs 30%; P<.05). Even excluding all articles with a main focus on new laws/policies, 
there was still a significantly greater number (16 vs 5; p<.05) and percentage (42% vs 18%; p<.05) 
of articles mentioning tanning beds risks in the POST period. Therefore, the California indoor 
tanning ban was associated with a lasting effect on journalists — even for articles unrelated to the 
legislation — that had the potential to increase awareness for all readers about the link between 
indoor tanning and skin cancer.    
346
Initial findings for the effectiveness of using IVIG to treat Stevens-Johnson syndrome and 
toxic epidermal necrolysis
M McEnery-Stonelake,1 A Mostaghimi2 and D Kroshinsky3 1 School of Medicine, University 
of Massachusetts Medical School, Worcester, MA, 2 Department of Dermatology, Brigham 
and Women’s Hospital, Boston, MA and 3 Department of Dermatology, Massachusetts 
General Hospital, Boston, MA
This is a retrospective review of adult patients diagnosed with SJS, SJS/TEN, and TEN at two large 
Boston medical centers over close to 10 years. Both institutions are large academic medical centers, 
contain a burn center and share the same dermatology residents, but only one site (Site 2) utilizes 
IVIG, either alone or in combination with systemic steroids. Chart review assessed treatment course 
and outcome up to three months after discharge. 73 patients met inclusion criteria, with 51 (69.9%) 
patients from Site 1 and 22 (30.1%) patients from Site 2. The overall Site 1 mortality was 23.5%. 
66.7% of patients who died had received oral steroids, the remainder were treated with supportive 
care. 71.4% of TEN patients at Site 1 who died had received oral steroids. The mortality rate for 
TEN patients treated with systemic steroids was 38.5%. The overall mortality rate at Site 2 was 
22.7%. Of these patients, 60.0% had received only IVIG, 20.0% had received only oral steroids, 
and 20.0% had received both IVIG and oral steroids. There was a 33.3% mortality among TEN 
patients at Site 2 who were treated with IVIG alone and a 25.0% mortality among patients treated 
with both IVIG and steroids. 50.0% of TEN patients treated at Site 2 who died received IVIG alone 
and 50.0% were treated with both IVIG and oral steroids. Only one TEN patient at site 2 was treated 
with oral steroids alone, and survived. 39.2% received supportive care alone at Site 1 with four 
deaths. 13.6% of patients at site 2 received supportive care with no deaths. These findings suggest 
that patients treated with IVIG alone or in combination with oral steroids may be associated with 
improved rates of survival when compared to oral steroid treatment alone, however supportive care 
may be efficacious as well. This study is limited by its small size and retrospective nature. Similar 
large multicenter investigations are needed.    
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Underestimating disease burden: Trends in basal cell carcinoma incidence rates
MM Asgari, H Moffett, T Ray and C Quesenberry Division of Research, Kaiser Permanente, 
Oakland, CA
The incidence of basal cell carcinoma (BCC) has been dramatically increasing globally, but inci-
dence rates in the United States are largely unknown because BCCs are not reportable tumors. We 
sought to report annual BCC incidence and percent change over time using a previously validated 
BCC registry based on electronic pathology reports from Kaiser Permanente Northern California 
(KPNC). BCCs were identified from a validated KPNC BCC Registry using electronic pathology 
reports from 1998-2012. Age-and sex-standardized incidence rate (IRs) were calculated based 
on US 2000 census data. The overall BCC IR at KPNC steadily increased from a 418/100,000 
person-years in 1998 to 535/100,000 in 2012. The overall standardized incidence rate for BCCs 
in the US population for 2012 was 448/100,000, much higher than previously reported estimates. 
The rate of increase of BCC incidence was steepest for men and those greater than age 80. There 
was no significant change in BCC incidence among those <40 and of non-white race during the 
study period. BCCs and their treatment pose an increasing burden to the healthcare system. Our 
study allows for a more accurate estimate of the incidence and disease burden of BCCs and their 
changing epidemiology.    
   
      
      
